

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2006 (31.08.2006)

PCT

(10) International Publication Number
WO 2006/089872 A1

(51) International Patent Classification:

C07D 309/10 (2006.01) A61K 31/4155 (2006.01)
C07D 405/10 (2006.01) A61K 31/422 (2006.01)
C07D 409/10 (2006.01) A61K 31/4245 (2006.01)
C07D 413/10 (2006.01) A61K 31/427 (2006.01)
C07D 417/10 (2006.01) A61K 31/443 (2006.01)
A61K 31/351 (2006.01) A61K 31/506 (2006.01)
A61K 31/381 (2006.01) A61K 31/501 (2006.01)
A61K 31/41 (2006.01)

(21) International Application Number:

PCT/EP2006/060098

(22) International Filing Date:

20 February 2006 (20.02.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

05003871.0 23 February 2005 (23.02.2005) EP

(71) Applicant (for all designated States except DE, US):
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Str. 173, 55216 Ingelheim Am Rhein (DE).

(71) Applicant (for DE only): **BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG** [DE/DE]; Binger Str. 173, 55216 Ingelheim Am Rhein (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HIMMELSBACH, Frank** [DE/DE]; Ahornweg 16, 88441 Mittelbiberach (DE). **ECKHARDT, Matthias** [DE/DE]; Kirschenweg 7, 88400 Biberach (DE). **EICKELMANN, Peter** [DE/DE];

Nelkenweg 9, 88441 Mittelbiberach (DE). **THOMAS, Leo** [DE/DE]; Georg-Schinbain-str. 221, 88400 Biberach (DE). **BARSOUMIAN, Edward Leon** [US/JP]; 2-6-18-801 Nishi-Midorigaoka, Toyonaka, Osaka 560-0005 (JP).

(74) Agents: **HAMMANN, Heinz** et al.; Binger Str. 173, 55216 Ingelheim Am Rhein (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GLUCOPYRANOSYL-SUBSTITUTED (HETERO)ARYLETHYNYL-BENZYL-BENZENE DERIVATIVES AND USE THEREOF AS SODIUM-DEPENDENT GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS




(57) Abstract: Glucopyranosyl-substituted (hetero)arylethynyl-benzene derivatives of the general formula (I) where the groups R¹ to R⁶ as well as R^{7a}, R^{7b}, R^{7c} are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are SGLT2 inhibitors suitable for the treatment of metabolic disorders.

WO 2006/089872 A1

GLUCOPYRANOSYL-SUBSTITUTED ((HETERO)ARYLETHYNYL-BENZYL)-BENZENE DERIVATIVES
AND USE THEREOF AS SODIUM-DEPENDENT GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS

- 5 The present invention relates to glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives of the general formula I



- 10 wherein the groups R¹ to R⁶ and R^{7a}, R^{7b}, R^{7c} are as defined hereinafter, including the tautomers, the stereoisomers, the mixtures thereof and the salts thereof. The invention further relates to pharmaceutical compositions containing a compound of formula I according to the invention as well as the use of a compound according to the invention for preparing a pharmaceutical composition for the treatment of metabolic disorders. In addition, the
- 15 invention relates to processes for preparing a pharmaceutical composition as well as a compound according to the invention.

In the literature, compounds which have an inhibitory effect on the sodium-dependent glucose cotransporter SGLT2 are proposed for the treatment of diseases, particularly

20 diabetes.

Glucopyranosyloxy- substituted aromatic groups and the preparation thereof and their possible activity as SGLT2 inhibitors are known from published International applications WO 98/31697, WO 01/27128, WO 02/083066, WO 03/099836, WO 2004/063209, WO

25 2004/080990, WO 2004/013118, WO 2004/052902, WO 2004/052903 and US application US 2003/0114390.

Aim of the invention

The aim of the present invention is to find new pyranosyloxy-substituted benzene derivatives, particularly those which are active with regard to the sodium-dependent glucose cotransporter SGLT, particularly SGLT2. A further aim of the present invention is to discover pyranosyloxy-substituted benzene derivatives which have a good to very good inhibitory effect on the sodium-dependent glucose cotransporter SGLT2 *in vitro* and/or *in vivo* and/or have good to very good pharmacological and/or pharmacokinetic and/or physicochemical properties.

- 10 A further aim of the present invention is to provide new pharmaceutical compositions which are suitable for the prevention and/or treatment of metabolic disorders, particularly diabetes.


The invention also sets out to provide a process for preparing the compounds according to the invention.

15

Other aims of the present invention will become apparent to the skilled man directly from the foregoing and following remarks.

Object of the invention

- 20 In a first aspect the present invention relates to glucopyranosyloxy-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives of general formula I



wherein

25

- 30 R^1 denotes hydrogen, fluorine, chlorine, bromine, iodine, C_{1-4} -alkyl, C_{2-6} -alkynyl, C_{1-4} -alkoxy, C_{2-4} -alkenyl- C_{1-4} -alkoxy, C_{2-4} -alkynyl- C_{1-4} -alkoxy, methyl substituted by 1 to 3 fluorine atoms, ethyl substituted by 1 to 5 fluorine atoms, methoxy substituted by 1 to 3 fluorine atoms, ethoxy substituted by 1 to 5 fluorine atoms, C_{1-4} -alkyl substituted by a hydroxy or C_{1-3} -alkoxy group, C_{2-4} -alkoxy substituted by a hydroxy or C_{1-3} -alkoxy group, C_{2-6} -alkenyl, C_{3-7} -cycloalkyl, C_{3-7} -cycloalkyl- C_{1-3} -alkyl, C_{3-7} -

cycloalkyloxy, C₃₋₇-cycloalkyl-C₁₋₃-alkoxy, C₅₋₇-cycloalkenyloxy, hydroxy, amino, nitro or cyano, while in the C₅₋₆-cycloalkyl groups a methylene group may be replaced by O;

5 R² denotes hydrogen, fluorine, chlorine, bromine, hydroxy, C₁₋₄-alkyl, C₁₋₄-alkoxy, cyano or nitro, while the alkyl or alkoxy group may be mono- or polysubstituted by fluorine, and

10 R³ denotes an aryl-group or a 5- or 6-membered monocyclic heteroaryl-group or a 8-, 9- or 10-membered bicyclic heteroaryl-group wherein said heteroaryl-groups have 1 to 4 heteroatoms independently selected from the group consisting of N, O and S; and wherein said heteroaryl-group may possess 1 or 2 carbonyl groups as part of the mono- or bicyclic aromatic ring-system; and

15 wherein an N-atom of the heteroaryl ring-system may be oxidized to form the corresponding N-oxide; and

wherein one or more methine groups in said aryl- and heteroaryl-group may be substituted independently of one another with a substituent L¹; and

20

wherein one or more imino-groups in said heteroaryl-group may be substituted independently of one another with a substituent R^N; and

25 R⁴, R⁵ independently of one another denote hydrogen, fluorine, chlorine, bromine, iodine, cyano, nitro, C₁₋₃-alkyl, C₁₋₃-alkoxy, or a methyl- or methoxy-group substituted by 1 to 3 fluorine atoms,

30 L¹ independently of one another are selected from among fluorine, chlorine, bromine, iodine, hydroxy, cyano, C₁₋₃-alkyl, difluoromethyl, trifluoromethyl, C₁₋₃-alkoxy, difluoromethoxy, trifluoromethoxy, amino, C₁₋₃-alkyl-amino and di(C₁₋₃-alkyl)-amino; and

R^N independently of one another are selected from among C₁₋₃-alkyl; and

35 R⁶, R^{7a},
R^{7b}, R^{7c} independently of one another have a meaning selected from among hydrogen, (C₁₋₁₈-alkyl)carbonyl, (C₁₋₁₈-alkyl)oxycarbonyl, arylcarbonyl and aryl-(C₁₋₃-alkyl)-

carbonyl, while the aryl-groups may be mono- or disubstituted independently of one another by identical or different groups L¹;

5 while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups which may be substituted as defined; and

while, unless otherwise stated, the above-mentioned alkyl groups may be straight-chain or branched,

10 the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof.

The compounds of general formula I according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibitory effect on the sodium-dependent glucose cotransporter SGLT, particularly SGLT2. Moreover
15 compounds according to the invention may have an inhibitory effect on the sodium-dependent glucose cotransporter SGLT1. Compared with a possible inhibitory effect on SGLT1 the compounds according to the invention preferably inhibit SGLT2 selectively. Furthermore the compounds according to this invention exhibit advantageous physicochemical properties, particularly a good tendency towards crystallization.

20

The present invention also relates to the physiologically acceptable salts of the compounds according to the invention with inorganic or organic acids.

This invention also relates to pharmaceutical compositions, containing at least one
25 compound according to the invention or a physiologically acceptable salt according to the invention, optionally together with one or more inert carriers and/or diluents.

This invention also relates to the use of at least one compound according to the invention or one of the physiologically acceptable salts thereof for preparing a pharmaceutical
30 composition which is suitable for the treatment or prevention of diseases or conditions which can be influenced by inhibiting the sodium-dependent glucose cotransporter SGLT, particularly SGLT2.

This invention also relates to the use of at least one compound according to the invention or
35 one of the physiologically acceptable salts thereof for preparing a pharmaceutical composition which is suitable for the treatment of metabolic disorders.

This invention also relates to the use of at least one compound according to the invention or one of the physiologically acceptable salts thereof for preparing a pharmaceutical composition for inhibiting the sodium-dependent glucose cotransporter SGLT, particularly SGLT2.

5

The invention further relates to a process for preparing a pharmaceutical composition according to the invention, characterised in that a compound according to the invention or one of the physiologically acceptable salts thereof is incorporated in one or more inert carriers and/or diluents by a non-chemical method.


10

The present invention also relates to a process for preparing the compounds of general formula I according to the invention, characterised in that

a) in order to prepare compounds of general formula I which are defined as hereinbefore and hereinafter,

15

a compound of general formula II



20 wherein

R' denotes H, C₁₋₄-alkyl, (C₁₋₁₈-alkyl)carbonyl, (C₁₋₁₈-alkyl)oxycarbonyl, arylcarbonyl and aryl-(C₁₋₃-alkyl)-carbonyl, wherein the alkyl or aryl groups may be mono- or polysubstituted by halogen;

25

R^{8a}, R^{8b},

R^{8c}, R^{8d} independently of one another have one of the meanings given hereinbefore and hereinafter for the groups R⁶, R^{7a}, R^{7b}, R^{7c}, denote a benzyl group or a R^aR^bR^cSi group or a ketal or acetal group, particularly an alkylidene or arylalkylidene ketal or acetal group, while in each case two adjacent groups R^{8a}, R^{8b}, R^{8c}, R^{8d} may form a cyclic ketal or acetal group or a 1,2-di(C₁₋₃-alkoxy)-1,2-di(C₁₋₃-alkyl)-

30

ethylene bridge, while the above-mentioned ethylene bridge forms, together with two oxygen atoms and the two associated carbon atoms of the pyranose ring, a substituted dioxane ring, particularly a 2,3-dimethyl-2,3-di(C₁₋₃-alkoxy)-1,4-dioxane ring, and while alkyl, aryl and/or benzyl groups may be mono- or polysubstituted by halogen or C₁₋₃-alkoxy, and while benzyl groups may also be substituted by a di-(C₁₋₃-alkyl)amino group; and

R^a, R^b, R^c independently of one another denote C₁₋₄-alkyl, aryl or aryl-C₁₋₃-alkyl, wherein the aryl or alkyl groups may be mono- or polysubstituted by halogen;


while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, preferably phenyl groups;

and wherein the groups R¹ to R⁵ and R⁶, R^{7a}, R^{7b}, R^{7c} are defined as hereinbefore and hereinafter;

is reacted with a reducing agent in the presence of a Lewis or Brønsted acid, while any protective groups present are cleaved simultaneously or subsequently; or

b) in order to prepare compounds of general formula I wherein R⁶, R^{7a}, R^{7b} and R^{7c} denote hydrogen,

a compound of general formula III



wherein R^{8a}, R^{8b}, R^{8c}, R^{8d} and R¹ to R⁵ are defined as hereinbefore and hereinafter, but at least one of the groups R^{8a}, R^{8b}, R^{8c}, R^{8d} does not denote hydrogen, is hydrolysed, and

if desired a compound of general formula I thus obtained wherein R^6 denotes a hydrogen atom, is converted by acylation into a corresponding acyl compound of general formula I, and/or


5 if necessary any protective group used in the reactions described above is cleaved and/or

if desired a compound of general formula I thus obtained is resolved into its stereoisomers and/or

10 if desired a compound of general formula I thus obtained is converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof.

This invention further relates to a process for preparing compounds of general formula II

15



wherein

20 R' denotes H, C_{1-4} -alkyl, $(C_{1-18}$ -alkyl)carbonyl, $(C_{1-18}$ -alkyl)oxycarbonyl, arylcarbonyl and aryl- $(C_{1-3}$ -alkyl)-carbonyl, wherein the alkyl or aryl groups may be mono- or polysubstituted by halogen;


R^{8a} , R^{8b} ,
 R^{8c} , R^{8d} independently of one another has one of the meanings given for the groups R^6 ,
 25 R^{7a} , R^{7b} , R^{7c} , denote a benzyl group or a $R^a R^b R^c Si$ group or a ketal or acetal group, while in each case two adjacent groups R^{8a} , R^{8b} , R^{8c} , R^{8d} may form a cyclic ketal or acetal group or may form, with two oxygen atoms of the pyranose ring, a substituted 2,3-oxydioxane ring, particularly a 2,3-dimethyl-2,3-di- $(C_{1-3}$ -alkoxy)-1,4-dioxane ring, and while alkyl, aryl and/or benzyl groups may be
 30 mono- or polysubstituted by halogen or C_{1-3} -alkoxy, and while benzyl groups may also be substituted by a di- $(C_{1-3}$ -alkyl)amino group; and

R^a , R^b , R^c independently of one another denote C_{1-4} -alkyl, aryl or aryl- C_{1-3} -alkyl, while the alkyl or aryl groups may be mono- or polysubstituted by halogen;

- 5 while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, preferably phenyl groups;


and R^1 to R^5 , R^6 , R^{7a} , R^{7b} , R^{7c} are defined as hereinbefore and hereinafter,

- 10 wherein an organometallic compound (V) which may be obtained by halogen-metal exchange or by inserting a metal in the carbon-halogen bond of a halogen-benzylbenzene compound of general formula IV



15

wherein Hal denotes Cl, Br and I and R^1 to R^5 are defined as hereinbefore and hereinafter, and optionally subsequent transmetallation, is added to a gluconolactone of general formula VI



20

wherein R^{8a} , R^{8b} , R^{8c} , R^{8d} are defined as hereinbefore and hereinafter, and

- 25 then the resulting adduct, is reacted, preferably *in situ*, with water or an alcohol R' -OH, while R' denotes optionally substituted C_{1-4} -alkyl, in the presence of an acid, such as for example methanesulphonic acid, sulphuric acid, hydrochloric acid, acetic acid or ammonium chloride, and optionally the product obtained in the reaction with water wherein R' denotes H is converted, in a subsequent reaction, with an acylating agent, such as for example the

corresponding acid chloride or anhydride, into the product of formula II wherein R' denotes (C₁₋₁₈-alkyl)carbonyl, (C₁₋₁₈-alkyl)oxycarbonyl, arylcarbonyl or aryl-(C₁₋₃-alkyl)-carbonyl, which may be substituted as specified.

- 5 The intermediate products listed, particularly those of formula IV, formula II and formula III, are also a subject of this invention.

Detailed Description of the invention

- 10 Unless otherwise stated, the groups, residues and substituents, particularly R¹ to R⁵, L1, R^N, R⁶, R^{7a}, R^{7b}, R^{7c}, R^{8a}, R^{8b}, R^{8c}, R^{8d}, are defined as above and hereinafter.



If residues, substituents or groups occur several times in a compound, as for example L1 and/or R^N, they may have the same or different meanings.

15

Some preferred meanings of individual groups and substituents of the compounds according to the invention will be given hereinafter.

20

The group -C≡C-R³ is preferably in the meta or para position to the -CH₂-bridge, so that compounds according to the following formulae I.1 and I.2, particularly formula I.2, are preferred:



The group R^1 preferably denotes hydrogen, fluorine, chlorine, bromine, C_{1-4} -alkyl, C_{1-4} -alkoxy, methyl substituted by 1 to 3 fluorine atoms, methoxy substituted by 1 to 3 fluorine atoms, C_{3-7} -cycloalkyloxy or C_{3-7} -cycloalkyl- C_{1-3} -alkoxy, while in the C_{5-6} -cycloalkyl groups a methylene group may be replaced by O.

Particularly preferred meanings of R^1 are hydrogen, fluorine, chlorine, methyl, methoxy, ethoxy, cyclopentyloxy, cyclohexyloxy, tetrahydrofuran-3-yloxy and tetrahydropyran-4-yl-oxy; particularly methyl and chlorine.

Preferred meanings of the group R^2 are hydrogen, fluorine, chlorine, methyl, methoxy, ethoxy and methyl substituted by 1 to 3 fluorine atoms.

Particularly preferred meanings of the group R^2 are hydrogen, fluorine, methoxy, ethoxy and methyl, particularly hydrogen.

The term aryl as used in the definition of the group R^3 denotes a phenyl- or a naphthyl-group, preferably a phenyl-group, which may be substituted with one or more substituents L1.

The term 5- or 6-membered monocyclic heteroaryl-group as used in the definition of the group R^3 preferably denotes a pyrrolyl, furanyl, thienyl, pyridyl or tetrazolyl group, or

a pyrrolyl, furanyl, thienyl or pyridyl group wherein one or two methine groups are replaced in each case by a nitrogen atom,

wherein said heteroaryl-groups may possess 1 or 2 carbonyl groups as part of the aromatic ring-system;

wherein an N-atom of the heteroaryl ring-system may be oxidized to form the corresponding N-oxide; and

wherein one or more methine-groups may be substituted independently of one another with a substituent L1; and

wherein one or more imino-groups may be substituted independently of one another with a substituent R^N .

The term 8-, 9- or 10-membered bicyclic heteroaryl-group as used in the definition of the group R^3 preferably denotes a indolyl, benzofuranyl, benzothiophenyl, quinolinylnyl or isoquinolinylnyl group, or

an indolyl, benzofuranyl, benzothiophenyl, quinolinylnyl or isoquinolinylnyl group wherein one to three methine groups are replaced in each case by a nitrogen atom,

wherein said heteroaryl-groups may possess 1 or 2 carbonyl groups as part of the aromatic ring-system;

wherein an N-atom of the heteroaryl ring-system may be oxidized to form the corresponding N-oxide; and

wherein one or more methine-groups may be substituted independently of one another with a substituent $L1$; and

wherein one or more imino-groups may be substituted independently of one another with a substituent R^N .

In heteroaryl-groups which possess 1 or 2 carbonyl groups as part of the aromatic ring-system each carbonyl group is preferably directly linked with an optionally substituted imino-group -NH-, thus forming a -NH-CO- group, or linked with an optionally substituted imino-group -NH- via an ethenylene-bridge, thus forming a -NH-CH=CH-CO- group.

Preferably the group R^3 denotes an optionally substituted aryl-group or an optionally substituted 5- or 6-membered monocyclic heteroaryl-group as defined above.

More preferably the group R^3 denotes phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, N-oxy-pyridyl, N-oxy-pyridazinyl, N-oxy-pyrazinyl, N-oxy-pyrimidinyl, furanyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, 1,2-dihydro-2-oxo-pyridinyl, 1,4-dihydro-4-oxo-pyridinyl, 2,3-dihydro-3-oxo-pyridazinyl, 1,2,3,6-tetrahydro-3,6-dioxo-pyridazinyl, 1,2-dihydro-2-oxo-pyrimidinyl, 3,4-dihydro-4-oxo-pyrimidinyl, 1,2,3,4-tetrahydro-2,4-dioxo-pyrimidinyl, 1,2-dihydro-2-oxo-pyrazinyl or 1,2,3,4-tetrahydro-2,3-dioxo-pyrazinyl,

wherein one or more methine-groups in said phenyl or said heteroaryl-groups may be substituted independently of one another with a substituent $L1$; and

wherein one or more imino-groups in said heteroaryl-groups may be substituted independently of one another with a substituent R^N .


- 5 Even more preferably the group R^3 denotes phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, [1,2,4]oxadiazolyl, 1H-[1,2,4]triazolyl, 2H-tetrazolyl, 1,2-dihydro-2-oxo-pyridinyl or 1,2,3,4-tetrahydro-2,4-dioxo-pyrimidinyl,


- 10 wherein one or more methine-groups in said phenyl or said heteroaryl-groups may be substituted independently of one another with a substituent L1; and

wherein one or more imino-groups in said heteroaryl-groups may be substituted independently of one another with a substituent R^N .

- 15 Most preferably the group R^3 is selected from the subformulas as depicted in Table A,

Table A





wherein, as described before, all tautomeric forms are included; and

wherein one or more methine-groups may be substituted independently of one another with a
 5 substituent L1; preferably wherein the methine groups are unsubstituted or one methine-group is substituted with L1; and

wherein one or more imino-groups may be substituted independently of one another with a
 substituent R^N.

10

Preferred meanings of the group L1 independently of one another are selected from among
 fluorine, chlorine, bromine, cyano, hydroxy, C₁₋₃-alkyl, difluoromethyl, trifluoromethyl, C₁₋₃-
 alkoxy, difluoromethoxy, trifluoromethoxy and di(C₁₋₃-alkyl)-amino.

15 Particularly preferred meanings of the group L1 are selected from fluorine, chlorine, hydroxy,
 methyl, trifluoromethyl, ethyl, methoxy, ethoxy and dimethylamino, particularly methyl, ethyl,
 methoxy, ethoxy and dimethylamino.

Preferred meanings of the group R^N independently of one another are selected from among
 20 methyl, ethyl, n-propyl and i-propyl; most preferably methyl and ethyl.

Preferred meanings of the group R⁴ are hydrogen and fluorine, particularly hydrogen.

Preferred meanings of the group R⁵ are hydrogen and fluorine, particularly hydrogen.




25


The group R⁶ preferably denotes according to the invention hydrogen, (C₁₋₈-
 alkyl)oxycarbonyl, C₁₋₈-alkylcarbonyl or benzoyl, particularly hydrogen or (C₁₋₆-
 alkyl)oxycarbonyl or C₁₋₆-alkylcarbonyl, particularly preferably hydrogen, methylcarbonyl,
 methoxycarbonyl or ethoxycarbonyl, most particularly preferably hydrogen.

The substituents R^{7a} , R^{7b} , R^{7c} preferably represent independently of one another hydrogen, (C₁₋₈-alkyl)oxycarbonyl, (C₁₋₁₈-alkyl)carbonyl or benzoyl, particularly hydrogen, (C₁₋₆-alkyl)oxycarbonyl or (C₁₋₈-alkyl)carbonyl, particularly preferably hydrogen, methoxycarbonyl, ethoxycarbonyl, methylcarbonyl or ethylcarbonyl. Most particularly preferably R^{7a} , R^{7b} and R^{7c} represent hydrogen.

The compounds of formula I wherein R^6 , R^{7a} , R^{7b} and R^{7c} according to the invention have a meaning other than hydrogen, for example C₁₋₈-alkylcarbonyl, are preferably suitable as intermediate products for the synthesis of compounds of formula I wherein R^6 , R^{7a} , R^{7b} and R^{7c} denote hydrogen.

Particularly preferred compounds of general formula I are selected from among formulae I.2a to I.2d, particularly I.2c:





while the groups R^1 to R^6 and R^{7a} , R^{7b} , R^{7c} have one of the meanings given previously, particularly have one of the given meanings specified as being preferred; and particularly

5

R^1 denotes hydrogen, fluorine, chlorine, bromine, C_{1-4} -alkyl, C_{1-4} -alkoxy, methyl substituted by 1 to 3 fluorine atoms, methoxy substituted by 1 to 3 fluorine atoms, C_{3-7} -cycloalkyloxy or C_{3-7} -cycloalkyl- C_{1-3} -alkoxy, while in the C_{5-6} -cycloalkyl groups a methylene group may be replaced by O; R^1 particularly preferably denotes

hydrogen, fluorine, chlorine, methyl, methoxy, ethoxy, cyclopentyloxy, cyclohexyloxy, tetrahydrofuran-3-yloxy or tetrahydropyran-4-yl-oxy; and

10

R^2 denotes hydrogen, fluorine, methoxy, ethoxy or methyl, particularly hydrogen; and

15

R^3 is selected from the group consisting of phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, N-oxy-pyridyl, N-oxy-pyridazinyl, N-oxy-pyrazinyl, N-oxy-pyrimidinyl, furanyl, thienyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, triazolyl, tetrazolyl, 1,2-dihydro-2-oxo-pyridinyl, 1,4-dihydro-4-oxo-pyridinyl, 2,3-dihydro-3-oxo-pyridazinyl, 1,2,3,6-tetrahydro-3,6-dioxo-pyridazinyl, 1,2-dihydro-2-oxo-pyrimidinyl, 3,4-dihydro-4-oxo-pyrimidinyl, 1,2,3,4-tetrahydro-2,4-dioxo-pyrimidinyl, 1,2-dihydro-2-oxo-pyrazinyl and 1,2,3,4-tetrahydro-2,3-dioxo-pyrazinyl; particularly selected from the subformulas as depicted in the above Table A;

20

wherein one or more methine-groups may be substituted independently of one another with a substituent $L1$; and

25

wherein one or more imino-groups may be substituted independently of one another with a substituent R^N ; and

30

R^4 denotes hydrogen or fluorine, particularly hydrogen; and

R^5 denotes hydrogen or fluorine, particularly hydrogen; and

L1 independently of one another are selected from among fluorine, chlorine, bromine, cyano, hydroxy, C₁₋₃-alkyl, difluoromethyl, trifluoromethyl, C₁₋₃-alkoxy, difluoromethoxy, trifluoromethoxy and di(C₁₋₃-alkyl)-amino; particularly selected from
5 among fluorine, chlorine, hydroxy, methyl, trifluoromethyl, ethyl, methoxy, ethoxy and dimethylamino; most preferably selected from among methyl, ethyl, methoxy, ethoxy and dimethylamino; and;

R^N independently of one another are selected from among C₁₋₃-alkyl; in particular
10 methyl and ethyl; and

R⁶ denotes hydrogen, (C₁₋₆-alkyl)oxycarbonyl, (C₁₋₆-alkyl)carbonyl or benzoyl, particularly hydrogen, methylcarbonyl, methoxycarbonyl or ethoxycarbonyl, most particularly preferably hydrogen; and
15

R^{7a}, R^{7b}, R^{7c} independently of one another represent hydrogen, (C₁₋₆-alkyl)oxycarbonyl, (C₁₋₈-alkyl)carbonyl or benzoyl, particularly hydrogen, methoxycarbonyl, ethoxycarbonyl, methylcarbonyl or ethylcarbonyl, particularly preferably hydrogen;

20 including the tautomers, the stereoisomers, the mixtures thereof and the salts thereof.


According to a variant of the embodiments given hereinbefore, other preferred compounds are those wherein the phenyl group which carries the substituent -C≡C-R³ has at least one other substituent R⁴ and/or R⁵ which is different from hydrogen. According to this variant,
25 particularly preferred compounds are those which have a substituent R⁴ representing fluorine.

The compounds of general formula I specified in the experimental section that follows, and the derivatives thereof, wherein R⁶ has a meaning according to the invention other than
30 hydrogen, particularly wherein R⁶ denotes ethoxycarbonyl or methoxycarbonyl, including the tautomers, the stereoisomers thereof and the mixtures thereof, are preferred according to another variant of this invention.

In the processes according to the invention the groups R¹, R², R³, R⁴ and R⁵ preferably have
35 the meanings specified hereinbefore as being preferred. Moreover R¹ preferably denotes H, C₁₋₃-alkyl or benzyl, particularly H, ethyl or methyl. The groups R^{8a}, R^{8b}, R^{8c} and R^{8d}


independently of one another preferably denote H, C₁₋₄-alkylcarbonyl or benzyl, particularly H, methylcarbonyl, ethylcarbonyl or benzyl.

The invention also relates to compounds of general formula IV, particularly of general formula IV'



wherein Hal denotes chlorine, bromine or iodine and the groups R¹, R², R³, R⁴ and R⁵ are as hereinbefore defined, as intermediate products or starting materials in the synthesis of the compounds according to the invention. Particularly preferably, the groups R¹, R², R³, R⁴ and R⁵ have the meanings given following formulae I.2a to I.2d.

The invention also relates to compounds of general formula II, particularly of general formula II'



wherein R', R^{8a}, R^{8b}, R^{8c}, R^{8d}, R¹, R², R³, R⁴ and R⁵ are defined as hereinbefore and hereinafter; particularly wherein R' denotes H, C₁₋₃-alkyl or benzyl, particularly H, ethyl or methyl; and the groups R^{8a}, R^{8b}, R^{8c} and R^{8d} independently of one another represent H, C₁₋₄-alkylcarbonyl or benzyl, particularly H, methylcarbonyl, ethylcarbonyl or benzyl and the groups R¹, R², R³, R⁴ and R⁵ are as hereinbefore defined, as intermediate products or starting materials in the synthesis of the compounds according to the invention. Particularly preferably the groups R¹, R², R³, R⁴ and R⁵ have the meanings given following formulae I.2a to I.2d.

Some terms used above and hereinafter to describe the compounds according to the invention will now be defined more closely.

The term halogen denotes an atom selected from the group consisting of F, Cl, Br and I, particularly F, Cl and Br.

5 The term C_{1-n}-alkyl, wherein n may have a value of 1 to 18, denotes a saturated, branched or unbranched hydrocarbon group with 1 to n C atoms. Examples of such groups include methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, tert-pentyl, n-hexyl, iso-hexyl, etc.

10 The term C_{2-n}-alkynyl, wherein n has a value of 3 to 6, denotes a branched or unbranched hydrocarbon group with 2 to n C atoms and a C≡C triple bond. Examples of such groups include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl etc. Unless otherwise stated alkynyl groups are connected to the remainder of the molecule via the C atom in position 1. Therefore terms such as 1-propynyl, 2-propynyl, 1-butynyl, etc. are
15 equivalent to the terms 1-propyn-1-yl, 2-propyn-1-yl, 1-butyn-1-yl, etc.. This also applies analogously to C_{2-n}-alkenyl groups.

The term C_{1-n}-alkoxy denotes a C_{1-n}-alkyl-O group, wherein C_{1-n}-alkyl is as hereinbefore defined. Examples of such groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-
20 butoxy, iso-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, iso-pentoxy, neo-pentoxy, tert-pentoxy, n-hexoxy, iso-hexoxy etc.

The term C_{1-n}-alkylcarbonyl denotes a C_{1-n}-alkyl-C(=O) group, wherein C_{1-n}-alkyl is as hereinbefore defined. Examples of such groups include methylcarbonyl, ethylcarbonyl, n-
25 propylcarbonyl, iso-propylcarbonyl, n-butylcarbonyl, iso-butylcarbonyl, sec-butylcarbonyl, tert-butylcarbonyl, n-pentylcarbonyl, iso-pentylcarbonyl, neo-pentylcarbonyl, tert-pentylcarbonyl, n-hexylcarbonyl, iso-hexylcarbonyl, etc.

30 The term C_{3-n}-cycloalkyl denotes a saturated mono-, bi-, tri- or spirocarbocyclic group with 3 to n C atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo[3.2.1]octyl, spiro[4.5]decyl, norpinyll, norbonyl, norcaryl, adamantyl, etc. Preferably the term C₃₋₇-cycloalkyl denotes saturated monocyclic groups.

35 The term C_{5-n}-cycloalkenyl denotes a C_{5-n}-cycloalkyl group which is as hereinbefore defined and additionally has at least one unsaturated C=C double bond.

The term C_{3-n}-cycloalkylcarbonyl denotes a C_{3-n}-cycloalkyl-C(=O) group wherein C_{3-n}-cycloalkyl is as hereinbefore defined.

5 The term tri-(C₁₋₄-alkyl)silyl comprises silyl groups which have identical or two or three different alkyl groups.

The term di-(C₁₋₃-alkyl)amino comprises amino groups which have identical or two different alkyl groups.

10 The term aryl preferably denotes naphthyl or phenyl, more preferably phenyl.


The nomenclature in structural formulas used above and hereinafter, in which a bond of a substituent of a cyclic group, as e.g. a phenyl ring, is shown towards the centre of the cyclic group, denotes, unless otherwise stated, that this substituent may be bound to any free
15 position of the cyclic group bearing an H atom.

The compounds according to the invention may be obtained using methods of synthesis known in principle. Preferably the compounds are obtained by the following methods according to the invention which are described in more detail hereinafter.

20

The glucose derivatives of formula II according to the invention may be synthesised from D-gluconolactone or a derivative thereof by adding the desired benzylbenzene compound in the form of an organometallic compound (Scheme 1).

25 Scheme 1: Addition of an Organometal Compound to a Gluconolactone




The reaction according to Scheme 1 is preferably carried out starting from a halogenated benzylbenzene compound of general formula IV, wherein Hal denotes chlorine, bromine, or iodine. Starting from the haloaromatic compound IV the corresponding organometallic compound (V) may be prepared either by means of a so-called halogen-metal exchange reaction or by inserting the metal into the carbon-halogen bond. The halogen-metal exchange with bromine or iodine-substituted aromatic groups may be carried out for example with an organolithium compound such as e.g. n-, sec- or tert-butyllithium and thereby yields the corresponding lithiated aromatic group. The analogous magnesium compound may also be generated by a halogen-metal exchange with a suitable Grignard reagent such as e.g. isopropylmagnesium bromide or diisopropylmagnesium. The reactions are preferably carried out between 0 and -100°C, particularly preferably between -10 and -80 °C, in an inert solvent or mixtures thereof, such as for example diethyl ether, tetrahydrofuran, toluene, hexane, or methylene chloride. The magnesium or lithium compounds thus obtained may optionally be transmetallated with metal salts such as e.g. cerium trichloride, to form alternative organometal compounds (V) suitable for addition. Alternatively, the organometallic compound (V) may also be prepared by inserting a metal into the carbon-halogen bond of the haloaromatic compound IV. Metals such as e.g. lithium or magnesium are suitable for this. The addition of the organometallic compound V to gluconolactone or derivatives thereof of formula VI is preferably carried out at temperatures between 0 and -100°C, particularly preferably at -30 to -80°C, in an inert solvent or mixtures thereof, to obtain the compound of formula II. The lithiation and/or coupling reaction may also be carried out in microreactors and/or micromixers in order to avoid low temperatures; for example analogously to the processes described in WO 2004/076470. Suitable solvents for the addition of the metallated phenyl group to the appropriately protected gluconolactone are e.g. diethyl ether, toluene, methylene chloride, hexane, tetrahydrofuran or mixtures thereof. The addition reactions may be carried out without any further adjuvants or in the case of sluggishly reacting coupling partners in the presence of Lewis acids such as e.g. $\text{BF}_3 \cdot \text{OEt}_2$ or Me_3SiCl (see M. Schlosser, *Organometallics in Synthesis*, John Wiley & Sons, Chichester/New York/Brisbane/Toronto/Singapore, 1994). Preferred definitions of the groups R^{8a} , R^{8b} , R^{8c} and R^{8d} are benzyl, substituted benzyl, trialkylsilyl, particularly preferably trimethylsilyl, triisopropylsilyl, 4-methoxybenzyl and benzyl. If two adjacent groups of the group consisting of R^{8a} , R^{8b} , R^{8c} and R^{8d} are linked together, these two groups are preferably part of a benzylideneacetal, 4-methoxybenzylideneacetal, isopropylketal or constitute a 2,3-dimethoxy-butylene group which is linked via the 2 and 3 positions of the butane with the adjacent oxygen atoms of the pyranose ring. The group R' preferably denotes hydrogen or C_{1-4} -alkyl, particularly preferably hydrogen, methyl or ethyl. The group R' is inserted after the addition of the organometallic compound V or a derivative thereof to the gluconolactone VI.

For this purpose the reaction solution is treated with an alcohol such as e.g. methanol or ethanol or water in the presence of an acid such as e.g. methanesulphonic acid, toluenesulphonic acid, sulphuric acid, or hydrochloric acid.

- 5 The synthesis of haloaromatic compound of formula IV may be carried out using standard transformations in organic chemistry or at least methods known from the specialist literature in organic synthesis (see inter alia J. March, *Advanced Organic Reactions, Reactions, Mechanisms, and Structure*, 4th Edition, John Wiley & Sons, Chichester/New York/Brisbane/Toronto/Singapore, 1992 and literature cited therein). More specifically, the
- 10 use of transition metals and organo metal compounds for the synthesis of aromatic compounds has been detailed in different monographs (see e.g. L. Brandsma, S.F. Vasilevsky, H.D. Verkruijsse, *Application of Transition Metal Catalysts in Organic Synthesis*, Springer-Verlag, Berlin/Heidelberg, 1998; M. Schlosser, *Organometallics in Synthesis*, John Wiley & Sons, Chichester/New York/Brisbane/Toronto/Singapore, 1994; P.J. Stang, F. Diederich, *Metal-Catalyzed Cross-Coupling Reactions*, Wiley-VCH, Weinheim, **1997** and
- 15 references quoted therein). The synthesis strategies described in the following provide a demonstration of this, by way of example.

Scheme 2: Synthesis of Diarylketones


20



- Scheme 2 shows the preparation of a precursor compound that may serve for the synthesis of the haloaromatic compounds of formula IV and IVa, respectively, starting from a
- 25 benzoylchloride and a second aromatic group applying Friedel-Crafts acylation conditions or variations thereof. The second aromatic compound bears a substituent U selected from halogen such as chlorine, bromine, iodine, or a group that may subsequently be converted to a halogen atom or a pseudohalogen group, e.g. trifluoromethanesulfonate, or an alkyne unit. This classic reaction has a wide substrate scope and is commonly carried out in the
- 30 presence of a catalyst which is used in catalytic or stoichiometric amounts, such as e.g. $AlCl_3$, $FeCl_3$, iodine, iron, $ZnCl_2$, sulphuric acid, or trifluoromethanesulphonic acid. Instead of the benzoyl chloride the corresponding carboxylic acid, anhydride, ester or benzonitrile may be used as well. The reactions are preferentially carried out in chlorinated hydrocarbons such

as e.g. dichloromethane and 1,2-dichloroethane at temperatures from -30 to 120°C, preferably at 30 to 100°C. However, solvent-free reactions or reactions in a microwave oven are also possible.


5 Scheme 3: Synthesis of Diarylmethanes and Possible Precursor Compounds thereof



In Scheme 3 the term "Alk" denotes C₁₋₃-alkyl and each substituent R is independently selected from each other from the group consisting of H, C₁₋₃-alkyl and C₁₋₃-alkoxy, while the remaining groups R¹ to R⁵ are defined as hereinbefore. The Scheme 3 delineates the synthesis of diarylmethanes and possible precursor compounds thereof starting from a metallated phenyl group that bears a residue U that is selected from a group consisting of an

alkynyl residue, a halogen atom such as chlorine, bromine, iodine, pseudohalogen group such as e.g. trifluoromethanesulfonate, or a residue such as e.g. a silyl group or a masked or protected fromyl group, that is subsequently convertible into a halogen atom, pseudohalogen group, or an alkyne unit. Lithium or magnesium substituted aromatic compounds may be synthesized from chlorinated, brominated, or iodinated aromats by a halogen-metal exchange reaction with e.g. butyllithium, isopropylmagnesiumhalogenide, or diisopropylmagnesium or by insertion of the elemental metal into the halogen-carbon bond. The corresponding boron substituted compound such as e.g. boronic acid, boronic acid ester, or dialkylarylborane, is accessible from these metallated phenyl groups by reaction with a boron electrophile such as e.g. boronic acid ester or a derivative thereof. In addition, the borylated aromatic compound may also be prepared from the corresponding halogenated or pseudohalogenated precursor and a diboron or borane compound through a transition metal, e.g. palladium, catalyzed reaction (see e.g. *Tetrahedron Lett.* **2003**, p. 4895-4898 and references quoted therein). The lithium or magnesium substituted phenyl compounds add to benzaldehydes (step 3) and benzoic acids or derivatives thereof (step 4) such as benzoic acid esters, benzamides such as e.g. of the Weinreb type, benzonitriles, or benzoyl chlorides. These reactions may principally be conducted without an additional transition metal catalyst or transmetalation to another metal such as e.g. cerium or zinc; sometimes the use of one of the latter alternatives is advantageous. Aryl boronic acids can be added to benzaldehydes by means of a rhodium catalyst furnishing the respective diarylmethanol (see e.g. *Adv. Synth. Catal.* **2001**, p. 343-350 and references quoted therein). Moreover, arylboronic acids, esters thereof, dialkylarylboranes, or aryltrifluoroborates may be coupled with benzoyl chlorides mediated by a transition metal such as e.g. palladium, a complex or a salt thereof delivering diarylketones. Metallated phenyl groups can be reacted with benzyl electrophiles such as benzyl chlorides, bromides, or iodides affording diarylmethanes. Lithium or magnesium derivatized phenyl compounds are reacted favorably but not always necessarily in the presence of a transition metal as e.g. copper, iron, or palladium (see e.g. *Org. Lett.* **2001**, 3, 2871-2874 and references quoted therein). Transmetalation from lithium or magnesium to e.g. boron, tin, silicon, or zinc furnishes e.g. the corresponding aromatic boronic acids, stannanes, silanes or zinc compounds, respectively, that may undergo coupling with benzyl electrophiles, e.g. benzyl halogenides, phosphates, sulfonates, or carboxylic esters. The reaction is conducted in the presence of a transition metal, e.g. palladium, nickel, rhodium, copper, or iron (see *Tetrahedron Lett.* **2004**, p. 8225-8228 and references cited therein).


Scheme 4: Reduction of Diarylketones and Diarylmethanols to Diarylmethanes



In Scheme 4 the substituent R denotes C₁₋₃-alkyl or aryl while the remaining substituents R¹ to R⁵ are defined as hereinbefore.. Starting from the diarylketone or diarylmethanol the diarylmethane is accessible in one or two reaction steps (U is selected from a group comprising alkynyl residues, halogen atoms such as chlorine, bromine, iodine, pseudohalogen groups such as e.g. trifluoromethanesulfonate, or residues such as e.g. silyl groups or masked or protected formyl groups, that are subsequently convertible into a halogen atom, pseudohalogen group, or an alkyne unit). The diarylketone may be reduced to the diarylmethane in two steps via the corresponding diphenylmethanol or in one step. In the two-step variant the ketone is reduced with a reducing agent such as for example a metal hydride such as e.g. NaBH₄, LiAlH₄ or iBu₂AlH to form the alcohol. The resulting alcohol can be converted in the presence of a Lewis acid such as for example BF₃·OEt₂, trifluoroacetic acid, InCl₃ or AlCl₃ with a reducing agent such as e.g. Et₃SiH, NaBH₄, or Ph₂SiClH to the desired diphenylmethane. The one-step process starting from the ketone to obtain the diphenylmethane may be carried out e.g. with a silane such as e.g. Et₃SiH, a borohydride such as e.g. NaBH₄ or an aluminum hydride such as LiAlH₄ in the presence of a Lewis acid such as for example BF₃·OEt₂, tris(pentafluorophenyl)borane, trifluoroacetic acid, aluminum chloride or InCl₃. The reactions are preferably carried out in solvents such as e.g. halogenated hydrocarbons such as dichloromethane, toluene, or acetonitrile at temperatures of -30 to 150°C, preferably at 20 to 100°C. Reductions with hydrogen in the presence of a transition metal catalyst such as e.g. Pd on charcoal are another possible method of synthesis. Reductions according to Wolff-Kishner or variants thereof are also possible. The ketone is first of all converted with hydrazine or a derivative thereof, such as e.g. 1,2-bis(tert-

butyldimethylsilyl)hydrazine, into the hydrazone which breaks down under strongly basic reaction conditions and heating to form the diphenylmethane and nitrogen. The reaction may be carried out in one reaction step or after isolation of the hydrazone or a derivative thereof in two separate reaction steps. Suitable bases include e.g. KOH, NaOH or KOtBu in solvents such as e.g. ethyleneglycol, toluene, DMSO, 2-(2-butoxyethoxy)ethanol or t-butanol; solvent-free reactions are also possible. The reactions may be carried out at temperatures between 20 to 250°C, preferably between 80 to 200°C. An alternative to the basic conditions of the Wolff-Kishner reduction is the Clemmensen reduction which takes place under acidic conditions, which may also be used here. The alcohol function in diarylmethanol may also first be transformed into a leaving group such as e.g. chloride, bromide, iodide, acetate, phosphate, or sulfate; the subsequent reduction step to form the diarylmethane is widely described in the organic chemistry literature.


Scheme 5: Introduction of the Alkyne Moiety



X = e.g. Cl, Br, I, SiMe₃, OH

Y = e.g. Cl, Br, I, OSO₂CF₃, B(OH)₂, or


Hal = e.g. Cl, Br, I, OSO₂CF₃



Scheme 5 displays possible pathways to attach the alkyne residue to the peripheral phenyl group at various stages of the synthesis of the target molecules. The alkyne is preferentially introduced via a transition metal mediated coupling reaction of a terminal alkyne with a halogenated or pseudohalogenated phenyl group. One of the most popular coupling protocols to accomplish this transformation is the so-called Sonogashira coupling reaction. The reaction comprises the use of a copper and a palladium catalyst under inert gas conditions. A lot of alternative methods are known that include the employment of metal acetylides, e.g. zinc acetylides, alkynylstannanes, or alkynylsilanes, that may be prepared from the terminal alkynes prior the addition of the coupling partner (see P.J. Stang, F. Diederich, *Metal-Catalyzed Cross-Coupling Reactions*, Wiley-VCH, Weinheim, **1997**; *Angew. Chem. Int. Ed.* **2003**, 42, 1566-1568 and references quoted therein). The halogenated or pseudohalogenated aromatic compounds are accessible by known procedures. Electrophilic


aromatic substitution with a halogen electrophile replaces a hydrogen atom or silyl group on the benzene ring for the halogen. The replacement of a silyl group for chlorine, bromine, or iodine can be performed under very mild conditions making this kind of derivatized benzene attractive for late stage introduction of the halogen for alkyne appendage. Starting from phenols the corresponding pseudohalogenated benzene compounds are accessible by e.g. sulfonation with e.g. trifluoromethanesulfonic acid anhydride. All these syntheses are broadly detailed in the organic chemistry literature.

Scheme 6: Introduction of the Alkyne Moiety from an Aldehyde



An alternative introduction of the alkyne group is the synthesis starting from an aldehyde (Scheme 6). The aldehyde itself can be introduced as such, protected, or masked. Popular protective groups for the aldehyde function are acetals, but other protective groups may be used as well (see T. W. Greene, P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, Inc., New York, 1999). Suitable masks for the aldehyde function are e.g. olefins and thiazoles. The aldehyde can be converted to the alkyne via a one or two-step procedure. The most frequently used methods include the reactions of Corey-Fuchs, Wittig-Horner-Emmons, and Gilbert-Seyferth and modifications thereof (see *J. Org. Chem.* **2000**, p. 1889-1891; *J. Am. Chem. Soc.* **2002**, p. 11600-11601; *Synlett* **1996**, p. 521-522 and references cited therein). The group R³ is finally attached to the terminal alkyne via a transition metal catalyzed coupling.

In order to prepare compounds of general formula I, in process a) according to the invention, a compound of general formula II




wherein R', R¹ to R⁵ are as hereinbefore defined and

R^{8a}, R^{8b}, R^{8c}, R^{8d} are as hereinbefore defined and independently of one another represent for example acetyl, pivaloyl, benzoyl, tert-butoxycarbonyl, benzyloxycarbonyl, trialkylsilyl, benzyl or substituted benzyl or in each case two adjacent groups R^{8a}, R^{8b}, R^{8c}, R^{8d} form a benzylideneacetal or isopropylideneacetal or a 2,3-dimethoxy-butylene group which is linked via position 2 and 3 of the butylene group to the oxygen atoms of the pyranose ring and forms with them a substituted dioxane,

which may be obtained as hereinbefore described, is reacted with a reducing agent in the presence of a Lewis or Brønsted acid.

Suitable reducing agents for the reaction include for example silanes, such as triethyl, tripropyl, triisopropyl or diphenylsilane, sodium borohydride, sodium cyanoborohydride, zinc borohydride, boranes, lithium aluminium hydride, diisobutylaluminium hydride or samarium iodide. The reductions are carried out without or in the presence of a suitable Brønsted acid, such as e.g. hydrochloric acid, toluenesulphonic acid, trifluoroacetic acid or acetic acid, or Lewis acid, such as e.g. boron trifluoride etherate, trimethylsilyltriflate, titanium tetrachloride, tin tetrachloride, scandium triflate or zinc iodide. Depending on the reducing agent and the acid the reaction may be carried out in a solvent, such as for example methylene chloride, chloroform, acetonitrile, toluene, hexane, diethyl ether, tetrahydrofuran, dioxane, ethanol, water or mixtures thereof at temperatures between -60°C and 120°C. One particularly suitable combination of reagents consists for example of triethylsilane and boron trifluoride etherate, which is conveniently used in acetonitrile or dichloromethane at temperatures of -60°C and 60°C. Moreover, hydrogen may be used in the presence of a transition metal catalyst, such as e.g. palladium on charcoal or Raney nickel, in solvents such as tetrahydrofuran, ethyl acetate, methanol, ethanol, water or acetic acid, for the transformation described.

Alternatively, in order to prepare compounds of general formula I according to process b) according to the invention, in a compound of general formula III



5

wherein R¹ to R⁵ are as hereinbefore defined and

R^{8a} to R^{8d} denote one of the protective groups defined hereinbefore, such as e.g. an acyl, arylmethyl, acetal, ketal or silyl group, and which may be obtained for example by reduction from the compound of formula II as hereinbefore described, the protective groups are

10

cleaved.

Any acyl protecting group used is cleaved for example hydrolytically in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in

15 the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120°C, preferably at temperatures between 10 and 100°C. A trifluoroacetyl group is preferably cleaved by treating with an acid such as hydrochloric acid, optionally in the presence of a solvent such as acetic acid at temperatures between 50 and

20 120°C or by treating with sodium hydroxide solution optionally in the presence of a solvent such as tetrahydrofuran or methanol at temperatures between 0 and 50°C.

Any acetal or ketal protecting group used is cleaved for example hydrolytically in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or

25 dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120°C, preferably at temperatures between 10 and 100°C.

A trimethylsilyl group is cleaved for example in water, an aqueous solvent mixture or a lower alcohol such as methanol or ethanol in the presence of a base such as lithium hydroxide,

30 sodium hydroxide, potassium carbonate or sodium methoxide.

In aqueous or alcoholic solvents, acids such as e.g. hydrochloric acid, trifluoroacetic acid or acetic acid are also suitable. For cleaving in organic solvents, such as for example diethyl ether, tetrahydrofuran or dichloromethane, it is also suitable to use fluoride reagents, such as e.g. tetrabutylammonium fluoride.

5

A benzyl, methoxybenzyl or benzyloxycarbonyl group is advantageously cleaved hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures
10 between 0 and 100°C, but preferably at ambient temperatures between 20 and 60°C, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar. A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisole.

15

A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid or by treating with iodotrimethylsilane optionally using a solvent such as methylene chloride, dioxane, methanol or diethylether.

20

In the reactions described hereinbefore, any reactive groups present such as ethynyl, hydroxy, amino, alkylamino or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.

For example, a protecting group for an ethynyl group may be the trimethylsilyl or triisopropyl group. The 2-hydroxisoprop-2-yl group may also be used as a protective group.

25

For example, a protecting group for a hydroxy group may be a trimethylsilyl, acetyl, trityl, benzyl or tetrahydropyranyl group.

30

Protecting groups for an amino, alkylamino or imino group may be, for example, a formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert.butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group.

35

Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for example, *cis/trans* mixtures may be resolved into their *cis* and *trans* isomers, and compounds with at least one optically active carbon atom may be separated into their enantiomers.

Thus, for example, the *cis/trans* mixtures may be resolved by chromatography into the *cis* and *trans* isomers thereof, the compounds of general formula I obtained which occur as racemates may be separated by methods known *per se* (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes and
5 compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known *per se*, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.

10 The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and
15 separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-
20 o-tolyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+) or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)-or (-)-menthyloxycarbonyl.

Furthermore, the compounds of formula I may be converted into the salts thereof, particularly
25 for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulphonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.

Moreover, the compounds obtained may be converted into mixtures, for example 1:1 or 1:2
30 mixtures with amino acids, particularly with alpha-amino acids such as proline or phenylalanine, which may have particularly favourable properties such as a high crystallinity.

The compounds according to the invention are advantageously also obtainable using the methods described in the examples that follow, which may also be combined for this purpose
35 with methods known to the skilled man from the literature, for example, particularly the methods described in WO 98/31697, WO 01/27128, WO 02/083066, WO 03/099836 and WO 2004/063209.

As already mentioned, the compounds of general formula I according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibitory effect on the sodium-dependent glucose cotransporter SGLT, preferably SGLT2.

The biological properties of the new compounds may be investigated as follows:

The ability of the substances to inhibit the SGLT-2 activity may be demonstrated in a test set-up in which a CHO-K1 cell line (ATCC No. CCL 61) or alternatively an HEK293 cell line (ATCC No. CRL-1573), which is stably transfected with an expression vector pZeoSV (Invitrogen, EMBL accession number L36849), which contains the cDNA for the coding sequence of the human sodium glucose cotransporter 2 (Genbank Acc. No. NM_003041) (CHO-hSGLT2 or HEK-hSGLT2). These cell lines transport ^{14}C -labelled alpha-methylglucopyranoside (^{14}C -AMG, Amersham) into the interior of the cell in sodium-dependent manner.

The SGLT-2 assay is carried out as follows:

CHO-hSGLT2 cells are cultivated in Ham's F12 Medium (BioWhittaker) with 10% foetal calf serum and 250 $\mu\text{g}/\text{ml}$ zeocin (Invitrogen), and HEK293-hSGLT2 cells are cultivated in DMEM medium with 10% foetal calf serum and 250 $\mu\text{g}/\text{ml}$ zeocin (Invitrogen). The cells are detached from the culture flasks by washing twice with PBS and subsequently treating with trypsin/EDTA. After the addition of cell culture medium the cells are centrifuged, resuspended in culture medium and counted in a Casy cell counter. Then 40,000 cells per well are seeded into a white, 96-well plate coated with poly-D-lysine and incubated overnight at 37°C , 5% CO_2 . The cells are washed twice with 250 μl of assay buffer (Hanks Balanced Salt Solution, 137 mM NaCl, 5.4 mM KCl, 2.8 mM CaCl_2 , 1.2 mM MgSO_4 and 10 mM HEPES (pH 7.4), 50 $\mu\text{g}/\text{ml}$ of gentamycin). 250 μl of assay buffer and 5 μl of test compound are then added to each well and the plate is incubated for a further 15 minutes in the incubator. 5 μl of 10% DMSO are used as the negative control. The reaction is started by adding 5 μl of ^{14}C -AMG (0.05 μCi) to each well. After 2 hours' incubation at 37°C , 5% CO_2 , the cells are washed again with 250 μl of PBS (20°C) and then lysed by the addition of 25 μl of 0.1 N NaOH (5 min. at 37°C). 200 μl of MicroScint20 (Packard) are added to each well and incubation is continued for a further 20 min at 37°C . After this incubation the radioactivity of the ^{14}C -AMG absorbed is measured in a Topcount (Packard) using a ^{14}C scintillation program.

To determine the selectivity with respect to human SGLT1 an analogous test is set up in which the cDNA for hSGLT1 (Genbank Acc. No. NM000343) instead of hSGLT2 cDNA is expressed in CHO-K1 or HEK293 cells.

- 5 The compounds of general formula I according to the invention may for example have EC₅₀ values below 1000 nM, particularly below 200 nM, most preferably below 50 nM.

In view of their ability to inhibit the SGLT activity, the compounds of general formula I according to the invention and the corresponding pharmaceutically acceptable salts thereof
10 are theoretically suitable for the treatment and/or preventative treatment of all those conditions or diseases which may be affected by the inhibition of the SGLT activity, particularly the SGLT-2 activity. Therefore, compounds according to the invention are particularly suitable for the prevention or treatment of diseases, particularly metabolic disorders, or conditions such as type 1 and type 2 diabetes mellitus, complications of
15 diabetes (such as e.g. retinopathy, nephropathy or neuropathies, diabetic foot, ulcers, macroangiopathies), metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, high blood pressure, chronic heart failure, edema and hyperuricaemia. In addition compounds according to the
20 invention are particularly suitable for the prevention or treatment of overweight, obesity (including class I, class II and/or class III obesity), visceral obesity and/or abdominal obesity. These substances are also suitable for preventing beta-cell degeneration such as e.g. apoptosis or necrosis of pancreatic beta cells. The substances are also suitable for improving or restoring the functionality of pancreatic cells, and also of increasing the number and size
25 of pancreatic beta cells. The compounds according to the invention may also be used as diuretics or antihypertensives and are suitable for the prevention and treatment of acute renal failure.

In particular, the compounds according to the invention, including the physiologically
30 acceptable salts thereof, are suitable for the prevention or treatment of diabetes, particularly type 1 and type 2 diabetes mellitus, and/or diabetic complications.

The dosage required to achieve the corresponding activity for treatment or prevention usually depends on the compound which is to be administered, the patient, the nature and gravity of
35 the illness or condition and the method and frequency of administration and is for the patient's doctor to decide. Expediently, the dosage may be from 1 to 100 mg, preferably 1 to 30 mg, by intravenous route, and 1 to 1000 mg, preferably 1 to 100 mg, by oral route, in

each case administered 1 to 4 times a day. For this purpose, the compounds of formula I prepared according to the invention may be formulated, optionally together with other active substances, together with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.

The compounds according to the invention may also be used in conjunction with other active substances, particularly for the treatment and/or prevention of the diseases and conditions mentioned above. Other active substances which are suitable for such combinations include for example those which potentiate the therapeutic effect of an SGLT antagonist according to the invention with respect to one of the indications mentioned and/or which allow the dosage of an SGLT antagonist according to the invention to be reduced. Therapeutic agents which are suitable for such a combination include, for example, antidiabetic agents such as metformin, sulphonylureas (e.g. glibenclamide, tolbutamide, glimepiride), nateglinide, repaglinide, thiazolidinediones (e.g. rosiglitazone, pioglitazone), PPAR-gamma-agonists (e.g. GI 262570) and antagonists, PPAR-gamma/alpha modulators (e.g. KRP 297), alpha-glucosidase inhibitors (e.g. acarbose, voglibose), DPPIV inhibitors (e.g. LAF237, MK-431), alpha2-antagonists, insulin and insulin analogues, GLP-1 and GLP-1 analogues (e.g. exendin-4) or amylin. The list also includes inhibitors of protein tyrosinephosphatase 1, substances that affect deregulated glucose production in the liver, such as e.g. inhibitors of glucose-6-phosphatase, or fructose-1,6-bisphosphatase, glycogen phosphorylase, glucagon receptor antagonists and inhibitors of phosphoenol pyruvate carboxykinase, glycogen synthase kinase or pyruvate dehydrokinase, lipid lowering agents such as for example HMG-CoA-reductase inhibitors (e.g. simvastatin, atorvastatin), fibrates (e.g. bezafibrate, fenofibrate), nicotinic acid and the derivatives thereof, PPAR-alpha agonists, PPAR-delta agonists, ACAT inhibitors (e.g. avasimibe) or cholesterol absorption inhibitors such as, for example, ezetimibe, bile acid-binding substances such as, for example, cholestyramine, inhibitors of ileac bile acid transport, HDL-raising compounds such as CETP inhibitors or ABC1 regulators or active substances for treating obesity, such as sibutramine or tetrahydrolipostatin, dexfenfluramine, axokine, antagonists of the cannabinoid1 receptor, MCH-1 receptor antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists or β 3-agonists such as SB-418790 or AD-9677 and agonists of the 5HT2c receptor.

Moreover, combinations with drugs for influencing high blood pressure, chronic heart failure or atherosclerosis such as e.g. A-II antagonists or ACE inhibitors, ECE inhibitors, diuretics, β -blockers, Ca-antagonists, centrally acting antihypertensives, antagonists of the alpha-2-adrenergic receptor, inhibitors of neutral endopeptidase, thrombocyte aggregation inhibitors and others or combinations thereof are suitable. Examples of angiotensin II receptor antagonists are candesartan cilexetil, potassium losartan, eprosartan mesylate, valsartan, telmisartan, irbesartan, EXP-3174, L-158809, EXP-3312, olmesartan, medoxomil, tasosartan, KT-3-671, GA-0113, RU-64276, EMD-90423, BR-9701, etc. Angiotensin II receptor antagonists are preferably used for the treatment or prevention of high blood pressure and complications of diabetes, often combined with a diuretic such as hydrochlorothiazide.

A combination with uric acid synthesis inhibitors or uricosurics is suitable for the treatment or prevention of gout.

A combination with GABA-receptor antagonists, Na-channel blockers, topiramate, protein-kinase C inhibitors, advanced glycation end product inhibitors or aldose reductase inhibitors may be used for the treatment or prevention of complications of diabetes.

The dosage for the combination partners mentioned above is usefully 1/5 of the lowest dose normally recommended up to 1/1 of the normally recommended dose.

Therefore, in another aspect, this invention relates to the use of a compound according to the invention or a physiologically acceptable salt of such a compound combined with at least one of the active substances described above as a combination partner, for preparing a pharmaceutical composition which is suitable for the treatment or prevention of diseases or conditions which can be affected by inhibiting the sodium-dependent glucose cotransporter SGLT. These are preferably metabolic diseases, particularly one of the diseases or conditions listed above, most particularly diabetes or diabetic complications.

The use of the compound according to the invention, or a physiologically acceptable salt thereof, in combination with another active substance may take place simultaneously or at staggered times, but particularly within a short space of time. If they are administered simultaneously, the two active substances are given to the patient together; while if they are used at staggered times the two active substances are given to the patient within a period of less than or equal to 12 hours, but particularly less than or equal to 6 hours.

Consequently, in another aspect, this invention relates to a pharmaceutical composition which comprises a compound according to the invention or a physiologically acceptable salt of such a compound and at least one of the active substances described above as combination partners, optionally together with one or more inert carriers and/or diluents.

5

Thus, for example, a pharmaceutical composition according to the invention comprises a combination of a compound of formula I according to the invention or a physiologically acceptable salt of such a compound and at least one angiotensin II receptor antagonist optionally together with one or more inert carriers and/or diluents.

10


The compound according to the invention, or a physiologically acceptable salt thereof, and the additional active substance to be combined therewith may both be present together in one formulation, for example a tablet or capsule, or separately in two identical or different formulations, for example as a so-called kit-of-parts.

15

In the foregoing and following text, H atoms of hydroxyl groups are not explicitly shown in every case in structural formulae. The Examples that follow are intended to illustrate the present invention without restricting it:

20 Preparation of the starting compounds:

Example I



(5-bromo-2-chloro-phenyl)-(4-methoxy-phenyl)-methanone

25

38.3 ml oxalyl chloride and 0.8 ml of dimethylformamide are added to a mixture of 100 g of 5-bromo-2-chloro-benzoic acid in 500 ml dichloromethane. The reaction mixture is stirred for 14 h, then filtered and separated from all volatile constituents in a rotary evaporator. The residue is dissolved in 150 ml dichloromethane, the solution is cooled to -5°C, and 46.5 g of anisole are added. Then 51.5 g of aluminum trichloride are added batchwise so that the temperature does not exceed 5°C. The solution is stirred for another 1 h at 1-5°C and then poured onto crushed ice. The organic phase is separated and the aqueous phase is extracted another three times with dichloromethane. The combined organic phases are

30


washed with aqueous 1 M hydrochloric acid, twice with 1 M sodium hydroxide solution and with brine. Then the organic phase is dried, the solvent is removed and the residue is recrystallised from ethanol.

Yield: 86.3 g (64% of theory)

5 Mass spectrum (ESI⁺): m/z = 325/327/329 (Br+Cl) [M+H]⁺


The following compound may be obtained analogously to Example I:

(1) (5-bromo-2-chloro-phenyl)-(4-iodo-phenyl)-methanone



10

Example II



4-bromo-1-chloro-2-(4-methoxy-benzyl)-benzene

15

A solution of 86.2 g (5-bromo-2-chloro-phenyl)-(4-methoxy-phenyl)-methanone and 101.5 ml triethylsilane in 75 ml dichloromethane and 150 ml acetonitrile is cooled to 10°C. Then with stirring 50.8 ml of boron trifluoride etherate are added so that the temperature does not exceed 20°C. The solution is stirred for 14 h at ambient temperature, before another 9 ml triethylsilane and 4.4 ml boron trifluoride etherate are added. The solution is stirred for a further 3 h at 45-50°C and then cooled to ambient temperature. A solution of 28 g potassium hydroxide in 70 ml of water is added and the mixture is stirred for 2 h. Then the organic phase is separated off and the aqueous phase is extracted another three times with diisopropylether. The combined organic phases are washed twice with 2 M potassium hydroxide solution and once with aqueous sodium chloride solution and then dried over sodium sulfate. After the solvent is removed the residue is washed with ethanol and dried at 60°C.

20

25


Yield: 50.0 g (61% of theory)

Mass spectrum (ESI⁺): m/z = 310/312/314 (Br+Cl) [M+H]⁺


30

The following compound may be obtained analogously to Example II :

(1) 4-bromo-1-chloro-2-(4-iodo-benzyl)-benzene



5


Example III4-(5-bromo-2-chloro-benzyl)-phenol

- 10 A solution of 14.8 g 4-bromo-1-chloro-2-(4-methoxy-benzyl)-benzene in 150 ml dichloromethane is cooled in an ice bath. Then 50 ml of a 1 M solution of boron tribromide in dichloromethane are added, and the solution is stirred for 2 h at ambient temperature. The solution is then cooled in an ice bath again, and saturated potassium carbonate solution is added dropwise. At ambient temperature the mixture is adjusted with aqueous 1 M
- 15 hydrochloric acid to a pH of 1, the organic phase is separated off and the aqueous phase is extracted another three times with ethyl acetate. The combined organic phases are dried over sodium sulfate, and the solvent is removed completely.

Yield: 13.9 g (98% of theory)

Mass spectrum (ESI⁺): m/z = 295/297/299 (Br+Cl) [M-H]⁺

20

Example IV[4-(5-bromo-2-chloro-benzyl)-phenoxy]-tert-butyl-dimethyl-silane

- 25 A solution of 13.9 g 4-(5-bromo-2-chloro-benzyl)-phenol in 140 ml dichloromethane is cooled in an ice bath. Then 7.54 g tert-butyldimethylsilylchlorid in 20 ml dichloromethane are added followed by 9.8 ml triethylamine and 0.5 g 4-dimethylaminopyridine. The solution is stirred for


16 h at ambient temperature and then diluted with 100 ml dichloromethane. The organic phase is washed twice with aqueous 1 M hydrochloric acid and once with aqueous sodium hydrogen carbonate solution and then dried over sodium sulfate. After the solvent is removed, the residue is filtered through silica gel (cyclohexane/ethyl acetate 100:1).

5 Yield: 16.8 g (87% of theory)

Mass spectrum (EI): $m/z = 410/412/414$ (Br+Cl) $[M]^+$


The following compound may be obtained analogously to Example IV

10 (1) [4-(5-bromo-2-methyl-benzyl)-phenoxy]-tert-butyl-dimethyl-silane



Mass spectrum (EI): $m/z = 390/392$ (Br) $[M]^+$

15 Example V



1-bromo-4-triisopropylsilyl-ethynyl-benzene


Under argon 11.6 ml triisopropylacetylen and 14.4 ml triethylamine followed by 0.2 g copper iodide and 0.73 g bis-(triphenylphosphine)-palladium dichloride are added to an oxygen-free solution of 15.0 g 1-bromo-4-iodo-benzene in 150 ml dry tetrahydrofuran. The solution is stirred for 16 h at ambient temperature and then filtered through Celite and evaporated down. The residue is chromatographed on silica gel (cyclohexane).

Yield: 17.4 g (100% of theory)

25 Mass spectrum (ESI⁺): $m/z = 336/338$ (Br) $[M]^+$

The following compound may be obtained analogously to Example V:


(1) [4-(5-bromo-2-chloro-benzyl)-phenylethynyl]-triisopropyl-silane
4-bromo-1-chloro-2-(4-iodo-benzyl)-benzene is used as starting material.



This compound may also be obtained according to Example X.

5

Example VI



(5-bromo-2-fluoro-phenyl)-{4-[(triisopropylsilyl)-ethynyl]-phenyl}-methanol

- 10 33.8 ml of a 1.6 M solution of n-butyllithium in hexane are added dropwise under argon to a solution of 17.4 g 1-bromo-4-triisopropylsilylethynyl-benzene in 120 ml dry tetrahydrofuran chilled to -78°C. The solution is stirred for 1 h at -70°C. Then 10.8 g 5-bromo-2-fluoro-benzaldehyde dissolved in 30 ml of tetrahydrofuran are added dropwise over 15 min. The resulting solution is left in the cooling bath to warm up overnight to ambient temperature.
- 15 Then water is added and the mixture is extracted with ethyl acetate. The combined organic phases are dried over sodium sulfate, and the solvent is removed. The residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 4:1).


Yield: 14.3 g (60% of theory)

Mass spectrum (ESI⁺): m/z = 461/463 (Br) [M+H]⁺

20


The following compounds may be obtained analogously to Example VI:

(1) (3-bromo-phenyl)-{4-[(triisopropylsilyl)-ethynyl]-phenyl}-methanol



Mass spectrum (ESI⁻): m/z = 487/489 (Br) [M+HCOO]⁻


(2) (5-bromo-2-methoxy-phenyl)-(4-[(triisopropylsilyl)-ethynyl]-phenyl)-methanol



5


Mass spectrum (ESI⁺): m/z = 473/475 (Br) [M+H]⁺

(3) (5-Bromo-2-chloro-phenyl)-(4-trimethylsilyl-phenyl)-methanol




10

(4) (3-bromo-4-methoxy-phenyl)-(4-[(triisopropylsilyl)-ethynyl]-phenyl)-methanol



Mass spectrum (ESI⁻): m/z = 517/519 (Br) [M+HCOO]⁻

Example VII[4-(5-bromo-2-fluoro-benzyl)-phenylethynyl]-triisopropyl-silane

- 5 A solution of 5.6 g (5-bromo-2-fluoro-phenyl)-{4-[(triisopropylsilyl)-ethynyl]-phenyl}-methanol and 4.1 ml triethylsilane in 50 ml dichloromethane is cooled in an ice bath. Then 4.7 ml trifluoroacetic acid are slowly added dropwise, and the solution is stirred for 4 h at ambient temperature. The solution is diluted with dichloromethane and washed with aqueous sodium hydrogen carbonate solution. After drying over sodium sulfate the solvent is removed and the
- 10 residue is purified using silica gel (cyclohexane).


Yield: 2.6 g (48% of theory)

Mass spectrum (EI): $m/z = 445/447$ (Br) $[M]^+$

The following compounds may be obtained analogously to Example VII:

15


(1) [4-(3-bromo-benzyl)-phenylethynyl]-triisopropyl-silane



Mass spectrum (ESI⁺): $m/z = 427/429$ (Br) $[M+H]^+$


20 (2) [4-(5-bromo-2-methoxy-benzyl)-phenylethynyl]-triisopropyl-silane

In a departure from the process described hereinbefore the reaction solution is stirred in the ice bath instead of at ambient temperature until the reaction is complete.




Mass spectrum (ESI⁺): $m/z = 457/459$ (Br) $[M+H]^+$

(3) [4-(5-Bromo-2-chloro-benzyl)-phenyl]-trimethyl-silane




5 (4) [4-(3-bromo-4-methoxy-benzyl)-phenylethynyl]-triisopropyl-silane

In a departure from the process described hereinbefore the reaction solution is stirred in the ice bath instead of at ambient temperature until the reaction is complete.



Mass spectrum (ESI⁺): m/z = 457/459 (Br) [M+H]⁺

10

Example VIII4-bromo-2-bromomethyl-1-chloro-benzene


15

4.0 g N-bromosuccinimide are slowly added to a solution of 5.0 g of 4-bromo-1-chloro-2-hydroxymethyl-benzene and 5.9 g triphenylphosphine in 50 ml of tetrahydrofuran chilled to 5°C. After 1 h stirring at ambient temperature the precipitate is filtered off and the solvent is eliminated in vacuo. The residue is purified through silica gel (cyclohexane/ethyl acetate

20 50:1).

Yield: 4.9 g (76% of theory)

Mass spectrum (EI): m/z = 282/284/286 (Br+Cl) [M]⁺


Example IX(4-iodo-phenylethynyl)-triisopropyl-silane

- 5 Under argon 18.0 g sodium iodide (dry), 0.6 g copper iodide and 0.8 g N,N'-dimethyl-cyclohexane-1,2-diamine are added to a solution of 20.0 g (4-bromo-phenylethynyl)-triisopropyl-silane. The solution is refluxed with stirring for 24 h and then cooled to ambient temperature. 1% aqueous ammonia solution (100 ml) is added and the resultant mixture is extracted with ethyl acetate. After drying over sodium sulfate the solvent is removed and the
- 10 residue is purified using silica gel (cyclohexane).

Yield: 21.0 g (92% of theory)

Mass spectrum (EI): $m/z = 384$ $[M]^+$

15 Example X

[4-(5-bromo-2-chloro-benzyl)-phenylethynyl]-triisopropyl-silane


- Under argon 0.66 ml of a 2 M solution of isopropylmagnesium chloride in tetrahydrofuran are
- 20 added dropwise to a solution of 0.50 g (4-iodo-phenylethynyl)-triisopropyl-silane in 2.2 ml dry tetrahydrofuran chilled to -25°C. The solution is stirred for 30 min at -25°C and then combined with 0.26 ml of a 1 M solution of CuCN*2 LiCl in tetrahydrofuran (prepared by dissolving CuCN and LiCl in the ratio 1:2). Shortly afterwards, 0.35 g 4-bromo-2-bromomethyl-1-chlorobenzene are added and the reaction mixture is brought up to -5°C in the
- 25 cooling bath. After 6 h stirring at -5°C the solution is heated to ambient temperature and stirred overnight. Then a mixture of saturated ammonium chloride solution and 25% ammonia solution (9:1) is added and the resulting mixture is added to water. The organic

phase is separated off and the aqueous phase is extracted with ethyl acetate, the combined organic phases are dried over sodium sulfate, and the solvent is removed. The residue is purified through silica gel (cyclohexane).

Yield: 0.28 g (50% of theory)

- 5 Mass spectrum (EI): $m/z = 461/463/465$ (Br+Cl) $[M+H]^+$

Example XI



10 2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyranone


A solution of 20 g D-glucono-1,5-lactone and 98.5 ml N-methylmorpholine in 200 ml of tetrahydrofuran is cooled to -5°C . Then 85 ml trimethylsilylchloride are added dropwise so that the temperature does not exceed 5°C . The solution is then stirred for 1 h at ambient

- 15 temperature, 5 h at 35°C and again for 14 h at ambient temperature. After the addition of 300 ml of toluene the solution is cooled in an ice bath, and 500 ml of water are added so that the temperature does not exceed 10°C . The organic phase is then separated off and washed in each case once with aqueous sodium dihydrogen phosphate solution, water and saturated aqueous sodium chloride solution. The solvent is removed and the residue is azeotropically
- 20 dried with toluene.

Yield: 52.5 g (approx. 90% pure)

Mass spectrum (ESI⁺): $m/z = 467$ $[M+H]^+$

Example XII



1-fluoro-4-(1-methoxy-D-glucopyranos-1-yl)-2-(4-triisopropylsilylethynyl-benzyl)-benzene

A solution of 4.46 g [4-(5-bromo-2-fluoro-benzyl)-phenylethynyl]-triisopropyl-silane in 30 ml dry diethyl ether is cooled to -80°C under argon. 11.8 ml of a 1.7 M solution of tert-butyllithium in pentane are slowly added dropwise to the cooled solution, and then the solution is stirred for 45 min at -80°C. Then a solution of 5.19 g of 2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyranone in 50 ml diethyl ether, chilled to -80°C, is added dropwise to this solution through a transfer needle. The resulting solution is stirred for 3 h at -78°C. Then a solution of 1.7 ml methanesulfonic acid in 50 ml of methanol is added, the cooling bath is removed and the solution is stirred for 16 h at ambient temperature. The solution is then neutralised with ethyldiisopropylamine and evaporated down to dryness. The residue is purified by chromatography on silica gel (dichloromethane/methanol 50:1->4:1).


Yield: 2.8 g (50% of theory)

Mass spectrum (ESI⁺): m/z = 576 [M+NH₄]⁺

The following compounds may be obtained analogously to Example XII:


(1) 1-methoxy-4-(1-methoxy-D-glucopyranos-1-yl)-2-(4-triisopropylsilylethynyl-benzyl)-benzene

Advantageously the reaction mixture is quenched with aqueous acetic acid solution instead of methanesulfonic acid.




Mass spectrum (ESI⁺): m/z = 588 [M+NH₄]⁺

(2) 1-chloro-4-(1-methoxy-D-glucopyranos-1-yl)-2-(4-triisopropylsilylethynyl-benzyl)-benzene



Mass spectrum (ESI⁺): m/z = 592/594 (Cl) [M+NH₄]⁺


(3) 1-methyl-4-(1-methoxy-D-glucopyranos-1-yl)-2-[4-(tert-butyl-dimethyl-silyloxy)-benzyl]-
5 benzene




Mass spectrum (ESI⁺): m/z = 522 [M+NH₄]⁺

(4) 1-methoxy-2-(1-methoxy-D-glucopyranos-1-yl)-4-(4-triisopropylsilylethynyl-benzyl)-
10 benzene

Advantageously the reaction mixture is quenched with aqueous acetic acid solution instead of methanesulfonic acid.



Mass spectrum (ESI⁺): m/z = 588 [M+NH₄]⁺

Example XIII

1-fluoro-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranos-1-yl)-2-(4-(4-triisopropylsilyl)ethynylbenzyl)-benzene

5

A solution of 0.8 g 1-fluoro-4-(1-methoxy-D-glucopyranos-1-yl)-2-(4-triisopropylsilylethynylbenzyl)-benzene and 0.5 ml triethylsilane in 6 ml dichloromethane and 10 ml acetonitrile is cooled to -10°C. 0.27 ml boron trifluoride etherate are added dropwise to the cooled solution. The solution is then stirred for 3 h in an ice bath. Aqueous sodium hydrogen carbonate

10 solution is added to the solution and then the resulting mixture is extracted with ethyl acetate. The organic phase is dried over sodium sulfate, the solvent is removed and the residue is taken up in 6 ml dichloromethane. Then 1.2 ml of pyridine, 1.3 ml of acetic anhydride and 8 mg of 4-dimethylaminopyridine are added. The solution is stirred for 1 h at ambient temperature and then combined with water. The mixture is extracted with dichloromethane,

15 the organic phase is washed with 1 M hydrochloric acid and dried over sodium sulfate. After the solvent is removed the residue is chromatographed on silica gel (cyclohexane/ethyl acetate 4:1->1:1).

Yield: 0.23 g (23% of theory)


Mass spectrum (ESI⁺): m/z = 714 [M+NH₄]⁺

20

The following compounds may be obtained analogously to Example XIII:


(1) 1-methoxy-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranos-1-yl)-2-(4-(4-triisopropylsilyl)ethynylbenzyl)-benzene

48




Mass spectrum (ESI⁺): m/z = 726 [M+NH₄]⁺

5 (2) 1-chloro-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranos-1-yl)-2-(4-triisopropylsilylethynyl-
benzyl)-benzene




Mass spectrum (ESI⁺): m/z = 730/732 (Cl) [M+NH₄]⁺

10 (3) 1-methyl-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranos-1-yl)-2-[4-(tert-butyl-dimethyl-
silyloxy)-benzyl]-benzene




Mass spectrum (ESI⁺): m/z = 660 [M+NH₄]⁺

15 (4) 1-methoxy-2-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranos-1-yl)-4-(4-triisopropylsilylethynyl-
benzyl)-benzene



Mass spectrum (ESI⁺): m/z = 726 [M+NH₄]⁺

Example XIV




5

1-methyl-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranos-1-yl)-2-(4-hydroxy-benzyl)-benzene

2.02 ml of a 1 M solution of tetrabutylammoniumfluoride in tetrahydrofuran are added to a solution of 1.3 g 1-methyl-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranos-1-yl)-2-[4-(tert-butyl-dimethyl-silyloxy)-benzyl]-benzene and 0.12 ml acetic acid in 10 ml of tetrahydrofuran. The solution is stirred for 30 min at ambient temperature, and then 50 ml ethyl acetate and 10 ml water are added. The organic layer was separated, washed with aqueous NaHCO₃ solution, and dried over MgSO₄. After removal of the solvent, the residue was recrystallized from ethyl acetate and petrol ether.

15 Yield: 0.90 g (84% of theory)

Mass spectrum (ESI⁺): m/z = 546 [M+NH₄]⁺

Example XV

1-(2,3,4,6-Tetra-O-acetyl-1-methoxy-D-glucopyranos-1-yl)-3-(4-triisopropylsilylphenylethynyl)-benzene


5

A solution of 2.6 g [4-(3-bromo-benzyl)-phenylethynyl]-triisopropyl-silane in 20 ml dry diethyl ether is cooled to -80°C under argon. 7.9 ml of a 1.7 M solution of tert-butyllithium in pentane are slowly added dropwise to the cooled solution, and then the solution is stirred for 30 min at -80°C. A solution of 3.2 g 2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyranone in 30 ml diethyl ether chilled to -80°C is then added dropwise to this solution through a transfer needle. The resulting solution is stirred for 2 h at -78°C and then another solution of 1.0 g 2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyranone in 10 ml diethyl ether chilled to -80°C is added dropwise. After another hour's stirring at -78°C a solution of 2 ml methanesulfonic acid in 20 ml of methanol is added, the cooling bath is removed and the solution is stirred for 16 h at ambient temperature. The solution is then neutralised with ethyldiisopropylamine, the solvent is removed and the residue is taken up in 50 ml of toluene. 8.5 ml ethyldiisopropylamine are added, and the solution is cooled in an ice bath. Then 4.3 ml acetic anhydride and 0.15 g 4-dimethylaminopyridine are added. The solution is stirred for 2 h at ambient temperature and then combined with aqueous sodium hydrogen carbonate solution. The resulting mixture is extracted with ethyl acetate, the organic phases are dried over sodium sulfate, and the solvent is removed. The residue is chromatographed on silica gel (cyclohexane/ethyl acetate 4:1->1:3).

20

Yield: 2.0 g (46% of theory)

Mass spectrum (ESI⁺): m/z = 726 [M+NH₄]⁺


Example XVI

1-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranos-1-yl)-3-(4-triisopropylsilylethynyl-benzyl)-
benzene

1.2 ml triethylsilane and 0.36 ml boron trifluoride etherate are added dropwise to an ice-cooled solution of 1.0 g 1-(2,3,4,6-tetra-O-acetyl-1-methoxy-D-glucopyranos-1-yl)-3-(4-triisopropylsilylethynyl-benzyl)-benzene and 25 µl water in 10 ml acetonitrile. The solution is then stirred for 3 h in the ice bath and for 1 h at ambient temperature. Then the solution is again cooled in an ice bath, and another 1.2 ml triethylsilane and 0.36 ml boron trifluoride etherate are added. The solution is stirred for a further 0.5 h in the ice bath and 2 h at ambient temperature. Aqueous sodium hydrogen carbonate solution is then added to the solution, and the resulting solution is extracted with ethyl acetate. The organic phase is dried over sodium sulfate and the solvent is removed.

Yield: 0.78 g (81% of theory)

Mass spectrum (ESI⁺): m/z = 696 [M+NH₄]⁺

Example XVII

1-fluoro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene

0.33 ml of a 1 M solution of tetrabutylammoniumfluorid in tetrahydrofuran are added to a solution of 0.23 g 1-fluoro-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranos-1-yl)-2-


(triisopropylsilylethynyl-benzyl)-benzene in 1.5 ml of tetrahydrofuran. The solution is stirred for 1 h at ambient temperature. Then 1 ml of methanol and 1.5 ml of 4 M potassium hydroxide solution are added and the solution is stirred for a further hour at ambient temperature. The solution is neutralised with 1 M hydrochloric acid and then the methanol is evaporated off. The residue is combined with aqueous sodium chloride solution and extracted with ethyl acetate. The organic extracts collected are dried over sodium sulfate, and the solvent is removed. The residue is chromatographed on silica gel (dichloromethane/methanol 19:1->2:1).

Yield: 0.060 g (49% of theory)

Mass spectrum (ESI^+): $m/z = 390$ $[\text{M}+\text{NH}_4]^+$


The following compounds may be obtained analogously to Example XVII:

(1) 1-(β -D-glucopyranos-1-yl)-3-(4-ethynyl-benzyl)-benzene




Mass spectrum (ESI^+): $m/z = 372$ $[\text{M}+\text{NH}_4]^+$

(2) 1-methoxy-4-(β -D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene



Mass spectrum (ESI^+): $m/z = 402$ $[\text{M}+\text{NH}_4]^+$


(3) 1-chloro-4-(β -D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene



Mass spectrum (ESI⁺): m/z = 406/408 (Cl) [M+NH₄]⁺


This compound may also be synthesized analogously to Example XX

5 (4) 2-(β-D-glucopyranos-1-yl)-1-methoxy-4-(4-ethynyl-benzyl)-benzene



Mass spectrum (ESI⁺): m/z = 402 [M+NH₄]⁺


(5) 4-(β-D-glucopyranos-1-yl)-3-(4-ethynyl-benzyl)-4-methyl-benzene



10

Mass spectrum (ESI⁺): m/z = 386 [M+NH₄]⁺

Example XVIII




15 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-hydroxybenzyl)-benzene

A solution of 4.0 g [4-(5-bromo-2-chloro-benzyl)-phenoxy]-tert-butyl-dimethyl-silane in 42 ml dry diethyl ether is cooled to -80°C under argon. 11.6 ml of a 1.7 M solution of tert-butyllithium in pentane are slowly added dropwise to the cooled solution, and then the solution is stirred for 30 min at -80°C. This solution is then added dropwise through a transfer
5 needle, which is cooled with dry ice, to a solution of 4.78 g 2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyranone in 38 ml diethyl ether chilled to -80°C. The resulting solution is stirred for 3 h at -78°C. Then a solution of 1.1 ml methanesulfonic acid in 35 ml of methanol is added and the solution is stirred for 16 h at ambient temperature. The solution is then neutralised with
10 solid sodium hydrogen carbonate, ethyl acetate is added and the methanol is removed together with the ether. Aqueous sodium hydrogen carbonate solution is added to the remaining solution which is extracted four times with ethyl acetate. The organic phases are dried over sodium sulfate and evaporated down. The residue is dissolved in 30 ml acetonitrile and 30 ml dichloromethane and the solution is cooled to -10°C. After the addition
15 of 4.4 ml triethylsilane 2.6 ml boron trifluoride etherate are added dropwise so that the temperature does not exceed -5°C. After the addition is complete the solution is stirred for another 5 h at -5 to -10°C and then quenched by the addition of aqueous sodium hydrogen carbonate solution. The organic phase is separated off and the aqueous phase is extracted
20 four times with ethyl acetate. The combined organic phase are dried over sodium sulfate, the solvent is removed and the residue is purified using silica gel. The product then obtained is an approx. 6:1 mixture of β/α which can be converted into the pure β -anomer by global acetylation of the hydroxy groups with acetic anhydride and pyridine in dichloromethane and recrystallising the product in ethanol. The product thus obtained is converted into the title compound by reacting in methanol with 4 M potassium hydroxide solution.

Yield: 1.6 g (46% of theory)

25 Mass spectrum (ESI⁺): m/z = 398/400 (Cl) [M+H]⁺

Example XIX



30 1-chloro-4-(β -D-glucopyranos-1-yl)-2-[4-(trifluoromethylsulphonyloxy)-benzyl]-benzene

10 mg 4-dimethylaminopyridine are added to a solution of 0.38 g 1-chloro-4-(β -D-glucopyranos-1-yl)-2-(4-hydroxybenzyl)-benzene, 0.21 ml triethylamine and 0.39 g N,N-bis-(trifluoromethanesulfonyl)-aniline in 10 ml dry dichloromethane. The solution is stirred for 4 h at ambient temperature and then combined with aqueous sodium chloride solution. It is
 5 extracted with ethyl acetate, the organic extracts are dried over sodium sulfate, and the solvent is removed. The residue is chromatographed on silica gel (dichloromethane/methanol 1:0- \rightarrow 4:1).


Yield: 0.33 g (64% of theory)

Mass spectrum (ESI⁺): m/z = 530/532 (Cl) [M+NH₄]⁺

10


The following compound may be obtained analogously to Example XIX:

(1) 1-methyl-4-(β -D-glucopyranos-1-yl)-2-[4-(trifluoromethylsulfonyloxy)-benzyl]-benzene



15

Example XX



1-chloro-4-(β -D-glucopyranos-1-yl)-2-(4-ethynylbenzyl)-benzene

20

25 mg of copper iodide, 44 mg of bis-(triphenylphosphine)-palladium dichloride, 0.30 ml triethylamine and finally 0.14 ml of trimethylsilylacetylene are added under argon to a solution of 0.32 g 1-chloro-4-(β -D-glucopyranos-1-yl)-2-[4-(trifluoromethylsulfonyloxy)-benzyl]-benzene in 3 ml of dimethylformamide. The flask is tightly sealed and stirred for 8 h
 25 at 90°C. Then another 25 mg of bis-(triphenylphosphine)-palladium dichloride and 0.1 ml trimethylsilylacetylene are added, and the solution is stirred for a further 10 h at 90°C. Then aqueous sodium hydrogen carbonate solution is added, the mixture is extracted three times


with ethyl acetate, and the combined organic phases are dried over sodium sulfate. After the solvent is removed the residue is dissolved in 5 ml of methanol and combined with 0.12 g potassium carbonate. The mixture is stirred for 1 h at ambient temperature and then neutralised with 1 M hydrochloric acid. Then the methanol is evaporated off, the residue is combined with aqueous sodium chloride solution and extracted with ethyl acetate. The organic extracts collected are dried over sodium sulfate, and the solvent is removed. The residue is chromatographed on silica gel (dichloromethane/methanol 1:0->5:1).

Yield: 0.095 g (40% of theory)

Mass spectrum (ESI⁺): m/z = 406/408 (Cl) [M+NH₄]⁺

This compound may also be obtained according to Example XVII.

Example XXI



2,3,4,6-Tetra-O-benzyl-D-glucopyranone

4 g freshly activated molecular sieve 4Å and 3.3 g N-methylmorpholine-N-oxide are added to a solution of 10.0 g 2,3,4,6-tetra-O-benzyl-α-D-glucopyranose in 140 ml dichloromethane.


The solution is stirred for 20 min at ambient temperature, before adding 0.3 g of

tetrapropylammonium perruthenate. After 2 h stirring at ambient temperature the solution is diluted with dichloromethane and filtered through Celite. The filtrate is washed with aqueous sodium thiosulfate solution and water and then dried over sodium sulfate. After the solvent is removed the residue is chromatographed through silica gel (cyclohexane/ethyl acetate 4:1).

Yield: 8.2 g (82% of theory)

Mass spectrum (ESI⁺): m/z = 539 [M+H]⁺

Example XXII




1-(2,3,4,6-Tetra-O-benzyl-1-hydroxy-D-glucopyranos-1-yl)-3-[4-(tert-butyl-dimethyl-silyloxy)-benzyl]-4-methyl-benzene

- 5 A solution of 0.34 g [4-(5-bromo-2-methyl-benzyl)-phenoxy]-tert-butyl-dimethyl-silane in 3 ml dry tetrahydrofuran is cooled to -80°C under argon. 0.54 ml of a 1.6 M solution of n-butyllithium in hexane are added dropwise to the cooled solution, and the solution is stirred for 1.5 h at -78°C . A solution of 0.43 g 2,3,4,6-tetra-O-benzyl-D-glucopyranone in 2.5 ml of tetrahydrofuran chilled to -80°C is added dropwise to this solution by means of transfer
- 10 needle. The resulting solution is stirred for 5 h at -78°C . The reaction is quenched with a solution of 0.1 ml acetic acid in 1 ml of tetrahydrofuran and heated to ambient temperature. Then aqueous sodium hydrogen carbonate solution is added and the mixture is extracted four times with ethyl acetate. The organic phases are dried over sodium sulfate and evaporated down. The residue is purified by chromatography on silica gel (cyclohexane/ethyl
- 15 acetate 15:1- \rightarrow 4:1).

Yield: 0.48 g (approx. 88% pure)

Mass spectrum (ESI^+): $m/z = 868$ $[\text{M}+\text{H}]^+$


Example XXIII



1-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranos-1-yl)-3-(4-hydroxy-benzyl)-4-methyl-benzene

A solution of 0.48 g (approx. 88% pure) 1-(2,3,4,6-tetra-O-benzyl-1-hydroxy-D-glucopyranosyl)-3-[4-(tert-butyl-dimethyl-silyloxy)-benzyl]-4-methyl-benzene in 3.5 ml dry acetonitrile is cooled to -40°C under argon. 0.13 ml triisopropylsilane and 0.08 ml boron trifluoride etherate are added dropwise to the cooled solution. The solution is stirred for 3 h at -35°C, before another 0.02 ml of triisopropylsilane and 0.01 ml of boron trifluoride etherate are added. After a further 2 h at -40°C aqueous potassium carbonate is added and the solution is stirred for 1 h at ambient temperature. Then it is diluted with water and extracted four times with ethyl acetate. The organic phase is dried over sodium sulfate, concentrated and chromatographed through silica gel (cyclohexane/ethyl acetate 10:1->4:1).
Yield: 0.24 g (68% of theory). Mass spectrum (ESI⁺): m/z = 738 [M+NH₄]⁺

Example XXIV



1-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranos-1-yl)-3-[4-(trifluoromethylsulfonyloxy)-benzyl]-4-methyl-benzene


A solution of 0.62 g 1-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranos-1-yl)-3-(4-hydroxy-benzyl)-4-methyl-benzene in 4.5 ml dry dichloromethane is cooled to -10°C under argon. 0.14 ml of pyridine and a solution of 0.3 g trifluoromethanesulfonic anhydride in 0.5 ml dichloromethane are added to the cooled solution. The solution is stirred for 0.5 h at -5 to -10°C, before aqueous sodium hydrogen carbonate solution is added. The mixture is extracted three times with dichloromethane, the combined organic phases are washed with aqueous 1 M hydrochloric acid and dried over sodium sulfate. After the solvent is removed the residue is chromatographed through silica gel (cyclohexane/ethyl acetate 15:1->7:1).

Yield: 0.62 g (84% of theory)

Mass spectrum (ESI⁺): m/z = 853 [M+H]⁺

The following compound may be obtained analogously to Example XVII:


(1) 1-methyl-4-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranos-1-yl)-2-[4-(trifluoromethylsulfonyloxy)-benzyl]-benzene



Mass spectrum (ESI⁺): m/z = 678 [M+NH₄]⁺

5

Example XXV



1-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranos-1-yl)-2-[4-(trimethylsilylethynyl)-benzyl]-4-methyl-benzene


10

Under argon, 17.3 mg copper iodide, 31.9 mg bis-(triphenylphosphine)-palladium dichloride, 0.22 ml triethylamine and finally 0.19 ml trimethylsilylacetylene are added to a solution of 0.30 g 1-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranos-1-yl)-3-[4-(trifluoromethylsulfonyloxy)-benzyl]-4-methyl-benzene in 1.5 ml of dimethylformamide. The flask is tightly sealed and stirred at 90°C over night. After 4 h additional 20 mg bis-(triphenylphosphine)-palladium dichloride and 0.2 ml trimethylsilylacetylene are added, and the mixture is further stirred at 90°C for 4 h. After cooling the reaction mixture to room temperature, the solvent is removed and the residue purified by chromatography on silica gel (cyclohexane/ethyl acetate 4:1->1:2).

20

Yield: 200 mg (72% of theory)

Mass spectrum (ESI⁺): m/z = 626 [M+H]⁺

Preparation of the end compounds:Example 15 1-(β-D-glucopyranos-1-yl)-3-[4-(pyridin-3-yl-ethynyl)-benzyl]-4-methyl-benzene

Under argon, 8.6 mg copper iodide, 15.9 mg bis-(triphenylphosphine)-palladium dichloride, 0.11 ml triethylamine and finally 47 mg pyridine-3-ylacetylene are added to a solution of 0.15 g 1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranos-1-yl)-3-[4-(trifluoromethylsulfonyloxy)-benzyl]-4-methyl-benzene in 1 ml of dimethylformamide. The flask is tightly sealed and stirred at 90°C over night. After cooling the reaction mixture to room temperature, 1 ml methanol followed by 0.34 ml aqueous 4 N sodium hydroxide solution are added. The reaction mixture is stirred for 30 min at room temperature and then neutralized with 2 N hydrochloric acid. The solution is diluted with 5 ml methanol and filtered through a plug of silica gel. The filtrate was concentrated, and the residue was purified by chromatography on silica gel (dichloromethane/methanol 1:0→2:1).


Yield: 12 mg (12% of theory)

Mass spectrum (ESI⁺): m/z = 446 [M+H]⁺

20 The following compounds may be obtained analogously to Example 1:

(2) 1-(β-D-glucopyranos-1-yl)-3-[4-(pyrimidin-5-yl-ethynyl)-benzyl]-4-methyl-benzene

61




Mass spectrum (ESI⁺): $m/z = 447$ [M+H]⁺

The compound was obtained from 1-(β -D-glucopyranos-1-yl)-3-(4-ethynyl-benzyl)-4-methyl-benzene and 5-bromo-pyrimidine.

5


(3) 1-Chloro-4-(β -D-glucopyranos-1-yl)-2-[4-(pyrimidin-5-yl-ethynyl)-benzyl]-benzene



Mass spectrum (ESI⁺): $m/z = 467/469$ (Cl) [M+H]⁺

10 The compound was obtained from 1-chloro-4-(β -D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene and 5-bromo-pyrimidine.


(4) 1-Chloro-4-(β -D-glucopyranos-1-yl)-2-[4-(2-methoxy-pyridin-5-yl-ethynyl)-benzyl]-benzene



15


Mass spectrum (ESI⁺): $m/z = 496/498$ (Cl) [M+H]⁺

The compound was obtained starting from 1-chloro-4-(β -D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene and 2-methoxy-5-bromo-pyridine.

(5) 1-Chloro-4-(β -D-glucopyranos-1-yl)-2-[4-(pyrazine-2-yl-ethynyl)-benzyl]-benzene


Mass spectrum (ESI⁺): m/z = ??? (Cl) [M+H]⁺

- 5 The compound was obtained starting from 1-chloro-4-(β -D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene and iodo-pyrazine.

(6) 1-Chloro-4-(β -D-glucopyranos-1-yl)-2-[4-(pyridine-3-yl-ethynyl)-benzyl]-benzene

- 10 Mass spectrum (ESI⁺): m/z = 466/468 (Cl) [M+H]⁺


The compound was obtained starting from 1-chloro-4-(β -D-glucopyranos-1-yl)-2-(4-trifluoromethylsulfonyloxy-benzyl)-benzene and 3-ethynyl-pyridine.

(7) 1-Chloro-4-(β -D-glucopyranos-1-yl)-2-[4-(pyridine-4-yl-ethynyl)-benzyl]-benzene

15


Mass spectrum (ESI⁺): m/z = 466/468 (Cl) [M+H]⁺

The compound was obtained starting from 1-chloro-4-(β -D-glucopyranos-1-yl)-2-(4-trifluoromethylsulfonyloxy-benzyl)-benzene and 4-ethynyl-pyridine.

(8) 1-Chloro-4-(β -D-glucopyranos-1-yl)-2-[4-(pyridine-2-yl-ethynyl)-benzyl]-benzene

Mass spectrum (ESI⁺): m/z = 466/468 (Cl) [M+H]⁺

- 5 The compound was obtained starting from 1-chloro-4-(β -D-glucopyranos-1-yl)-2-(4-trifluoromethylsulfonyloxy-benzyl)-benzene and 2-ethynyl-pyridine.


(9) 1-Chloro-4-(β -D-glucopyranos-1-yl)-2-[4-(1-methyl-1H-pyrazol-4-yl-ethynyl)-benzyl]-benzene

10

Mass spectrum (ESI⁺): m/z = 469/471 (Cl) [M+H]⁺

The compound was obtained starting from 1-chloro-4-(β -D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene and 4-iodo-1-methyl-1H-pyrazole.


15 (10) 1-Chloro-4-(β -D-glucopyranos-1-yl)-2-[4-(1H-pyrazol-4-yl-ethynyl)-benzyl]-benzene



Mass spectrum (ESI⁺): m/z = 455/457 (Cl) [M+H]⁺

The compound was obtained starting from 1-chloro-4-(β -D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene and 4-iodo-1H-pyrazole.


(11) 1-Chloro-4-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranos-1-yl)-2-[4-(thiophen-3-yl-ethynyl)-benzyl]-benzene



Mass spectrum (ESI⁺): m/z = 656/658 (Cl) [M+NH₄]⁺

The compound was obtained starting from 1-chloro-4-(2,3,4,6-tetra-O-acetyl- β -D-glucopyranos-1-yl)-2-(4-trifluoromethylsulfonyloxy-benzyl)-benzene and 3-ethynyl-thiophene.


(12) 1-Chloro-4-(β -D-glucopyranos-1-yl)-2-[4-(phenyl-ethynyl)-benzyl]-benzene



Mass spectrum (ESI⁺): m/z = 482/484 (Cl) [M+NH₄]⁺

The compound was obtained starting from 1-chloro-4-(β -D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene and iodobenzene.

(13) 1-Chloro-4-(β -D-glucopyranos-1-yl)-2-[4-(1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl-ethynyl)-benzyl]-benzene




Mass spectrum (ESI⁺): $m/z = 496/498$ (Cl) [M+H]⁺

The compound was obtained starting from 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynylbenzyl)-benzene and 5-iodo-1-methyl-1H-pyridin-2-one.

5

Example 14



1-Chloro-4-(β-D-glucopyranos-1-yl)-2-[4-(thiophen-3-ylethynyl)benzyl]-benzene

10

To a solution of 0.52 g 1-chloro-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranos-1-yl)-2-[4-(thiophen-3-ylethynyl)benzyl]-benzene in 9 mL methanol is added 0.85 mL of 4 M potassium hydroxide solution. The solution is stirred at ambient temperature for one hour and then neutralised with 1 M hydrochloric acid. After the methanol is evaporated the residue is combined with brine and the resultant mixture is extracted with ethyl acetate. The organic extracts are dried over sodium sulfate, and the solvent is removed. The residue is purified by chromatography on silica gel (dichloromethane/methanol 1:0→5:1).











15











Yield: 0.08 g (21% of theory)


Mass spectrum (ESI⁺): $m/z = 488/490$ (Cl) [M+NH₄]⁺

20

The following compounds are also prepared analogously to the above-mentioned Examples and other methods known from the literature:

Ex.	Structure	Ex.	Structure
15		16	
17		18	
19		20	
21		22	
23		24	

25		26	
27		28	
29		30	
31		32	
33		34	



Some examples of formulations will now be described in which the term "active substance" denotes one or more compounds according to the invention, including the salts thereof. In the case of one of the combinations with one or additional active substances as described previously, the term "active substance" also includes the additional active substances.

Example A

Tablets containing 100 mg of active substance

10 Composition:

1 tablet contains:

	active substance	100.0 mg
	lactose	80.0 mg
	corn starch	34.0 mg
15	polyvinylpyrrolidone	4.0 mg
	magnesium stearate	2.0 mg
		220.0 mg

Method of Preparation:

20 The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50°C it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.

Weight of tablet: 220 mg

25 Diameter: 10 mm, biplanar, faceted on both sides and notched on one side.

Example B

Tablets containing 150 mg of active substance

Composition:

30 1 tablet contains:

	active substance	150.0 mg
	powdered lactose	89.0 mg
	corn starch	40.0 mg
	colloidal silica	10.0 mg
5	polyvinylpyrrolidone	10.0 mg
	magnesium stearate	1.0 mg
		300.0 mg

Preparation:

- 10 The active substance mixed with lactose, corn starch and silica is moistened with a 20% aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45°C, are passed through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture.

Weight of tablet: 300 mg

- 15 die: 10 mm, flat

Example CHard gelatine capsules containing 150 mg of active substanceComposition:

- 20 1 capsule contains:
- | | | |
|---------------------|---------|----------|
| active substance | | 150.0 mg |
| corn starch (dried) | approx. | 180.0 mg |
| lactose (powdered) | approx. | 87.0 mg |
| magnesium stearate | | 3.0 mg |
| 25 | approx. | 420.0 mg |

Preparation:

- The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is
- 30 packed into size 1 hard gelatine capsules.

Capsule filling: approx. 320 mg

Capsule shell: size 1 hard gelatine capsule.

Example D

- 35 Suppositories containing 150 mg of active substance

Composition:

1 suppository contains:

	active substance	150.0 mg
	polyethyleneglycol 1500	550.0 mg
	polyethyleneglycol 6000	460.0 mg
	polyoxyethylene sorbitan monostearate	840.0 mg
5		2,000.0 mg

Preparation:

After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds.

10

Example EAmpoules containing 10 mg active substanceComposition:

	active substance	10.0 mg
15	0.01 N hydrochloric acid q.s.	
	double-distilled water	ad 2.0 ml

Preparation:

The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with common salt, filtered sterile and transferred into 2 ml ampoules.

20

Example FAmpoules containing 50 mg of active substanceComposition:

25	active substance	50.0 mg
	0.01 N hydrochloric acid q.s.	
	double-distilled water	ad 10.0 ml


Preparation:

The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules.

30

Claims

1. Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives of
 5 general formula I



wherein

10

R^1 denotes hydrogen, fluorine, chlorine, bromine, iodine, C_{1-4} -alkyl, C_{2-6} -alkynyl, C_{1-4} -alkoxy, C_{2-4} -alkenyl- C_{1-4} -alkoxy, C_{2-4} -alkynyl- C_{1-4} -alkoxy, methyl substituted by 1 to 3 fluorine atoms, ethyl substituted by 1 to 5 fluorine atoms, methoxy substituted by 1 to 3 fluorine atoms, ethoxy substituted by 1 to 5 fluorine atoms, C_{1-4} -alkyl substituted by a hydroxy or C_{1-3} -alkoxy group, C_{2-4} -alkoxy substituted by a hydroxy or C_{1-3} -alkoxy group, C_{2-6} -alkenyl, C_{3-7} -cycloalkyl, C_{3-7} -cycloalkyl- C_{1-3} -alkyl, C_{3-7} -cycloalkyloxy, C_{3-7} -cycloalkyl- C_{1-3} -alkoxy, C_{5-7} -cycloalkenyloxy, hydroxy, amino, nitro or cyano, while in the C_{5-6} -cycloalkyl groups a methylene group may be replaced by O;

15

20

R^2 denotes hydrogen, fluorine, chlorine, bromine, hydroxy, C_{1-4} -alkyl, C_{1-4} -alkoxy, cyano or nitro, while the alkyl or alkoxy group may be mono- or polysubstituted by fluorine, and

25

R^3 denotes an aryl-group or a 5- or 6-membered monocyclic heteroaryl-group or a 8-, 9- or 10-membered bicyclic heteroaryl-group wherein said heteroaryl-groups have 1 to 4 heteroatoms independently selected from the group consisting of N, O and S; and wherein said heteroaryl-group may possess 1 or 2 carbonyl groups as part of the mono- or bicyclic aromatic ring-system; and

30

wherein an N-atom of the heteroaryl ring-system may be oxidized to form the

corresponding N-oxide; and

wherein one or more methine groups in said aryl- and heteroaryl-group may be substituted independently of one another with a substituent L¹; and

5

wherein one or more imino-groups in said heteroaryl-group may be substituted independently of one another with a substituent R^N; and

10 R⁴, R⁵ independently of one another denote hydrogen, fluorine, chlorine, bromine, iodine, cyano, nitro, C₁₋₃-alkyl, C₁₋₃-alkoxy or a methyl- or methoxy-group substituted by 1 to 3 fluorine atoms,

L¹ independently of one another are selected from among fluorine, chlorine, bromine, 15 iodine, hydroxy, cyano, C₁₋₃-alkyl, difluoromethyl, trifluoromethyl, C₁₋₃-alkoxy, difluoromethoxy, trifluoromethoxy, amino, C₁₋₃-alkyl-amino and di(C₁₋₃-alkyl)-amino; and

R^N independently of one another are selected from among C₁₋₃-alkyl; and

20

R⁶, R^{7a},

R^{7b}, R^{7c} independently of one another have a meaning selected from among hydrogen, (C₁₋₁₈-alkyl)carbonyl, (C₁₋₁₈-alkyl)oxycarbonyl, arylcarbonyl and aryl-(C₁₋₃-alkyl)-carbonyl, while the aryl-groups may be mono- or disubstituted independently of one 25 another by identical or different groups L¹;


while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups which may be substituted as defined; and

30 while, unless otherwise stated, the above-mentioned alkyl groups may be straight-chain or branched,

the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof.

35

2. Glucopyranosyl-substituted (hetero)arylethynyl-benzene derivatives of general formula I.2



wherein the groups R^1 to R^6 and R^{7a} , R^{7b} and R^{7c} are defined as in claim 1.

5

3. Glucopyranosyl-substituted (hetero)arylethynyl-benzene derivatives according to claim 1 or 2, characterised in that the group R^3 is an aryl-group or a 5- or 6-membered monocyclic heteroaryl-group wherein the term 5- or 6-membered monocyclic heteroaryl-group denotes a pyrrolyl, furanyl, thienyl, pyridyl or tetrazolyl group, or

10

a pyrrolyl, furanyl, thienyl or pyridyl group wherein one or two methine groups are replaced in each case by a nitrogen atom,

15

wherein said heteroaryl-groups may possess 1 or 2 carbonyl groups as part of the aromatic ring-system;

wherein an N-atom of the heteroaryl ring-system may be oxidized to form the corresponding N-oxide; and

20

wherein one or more methine-groups in said phenyl or said heteroaryl-groups may be substituted independently of one another with a substituent $L1$; and

wherein one or more imino-groups in said heteroaryl-groups may be substituted independently of one another with a substituent R^N ;

25


wherein $L1$ and R^N are defined as in claim 1.

30

4. Glucopyranosyl-substituted (hetero)arylethynyl-benzene derivatives according to one or more of claims 1 to 3, characterised in that the group R^1 denotes hydrogen, fluorine, chlorine, bromine, C_{1-4} -alkyl, C_{1-4} -alkoxy, methyl substituted by 1 to 3 fluorine atoms, methoxy substituted by 1 to 3 fluorine atoms, C_{3-7} -cycloalkyloxy or C_{3-7} -cycloalkyl- C_{1-3} -alkoxy, while in the C_{5-6} -cycloalkyl groups a methylene group may be replaced by O.
5. Glucopyranosyl-substituted benzene derivatives according to one or more of claims 1 to 4, characterised in that the group R^2 denotes hydrogen, fluorine, chlorine, methyl, methoxy, ethoxy and methyl substituted by 1 to 3 fluorine atoms.
6. Glucopyranosyl-substituted benzene derivatives according to one or more of claims 1 to 5, characterised in that the groups R^4 and/or R^5 independently of one another represent hydrogen or fluorine.
7. Glucopyranosyl-substituted benzene derivatives according to one or more of claims 1 to 6, characterised in that the group R^6 denotes hydrogen, $(C_{1-8}\text{-alkyl})\text{oxycarbonyl}$, $C_{1-8}\text{-alkylcarbonyl}$ or benzoyl, preferably hydrogen.
8. Glucopyranosyl-substituted benzene derivatives according to one or more of claims 1 to 7, characterised in that the groups R^{7a} , R^{7b} , R^{7c} represent hydrogen.
9. Physiologically acceptable salts of the compounds according to at least one of claims 1 to 8 with inorganic or organic acids.
10. Pharmaceutical composition, containing a compound according to one or more of claims 1 to 8 or a physiologically acceptable salt according to claim 9, optionally together with one or more inert carriers and/or diluents.
11. Use of at least one compound according to one or more of claims 1 to 8 or a physiologically acceptable salt according to claim 9 for preparing a pharmaceutical composition which is suitable for the treatment or prevention of diseases or

conditions which can be influenced by inhibiting the sodium-dependent glucose cotransporter SGLT.

12. Use of at least one compound according to one or more of claims 1 to 8 or a
5 physiologically acceptable salt according to claim 9 for preparing a pharmaceutical composition which is suitable for the treatment or prevention of metabolic disorders.
13. Use according to claim 12, characterised in that the metabolic disorder is selected
10 from the group consisting of type 1 and type 2 diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, edema and hyperuricaemia.
14. Use of at least one compound according to at least one of claims 1 to 8 or a
15 physiologically acceptable salt according to claim 9 for preparing a pharmaceutical composition for inhibiting the sodium-dependent glucose cotransporter SGLT2.
15. Use of at least one compound according to at least one of claims 1 to 8 or a
20 physiologically acceptable salt according to claim 9 for preparing a pharmaceutical composition for preventing the degeneration of pancreatic beta cells and/or for improving and/or restoring the functionality of pancreatic beta cells.
16. Use of at least one compound according to at least one of claims 1 to 8 or a
25 physiologically acceptable salt according to claim 9 for preparing diuretics and/or antihypertensives.
17. Process for preparing a pharmaceutical composition according to claim 10,
30 characterised in that a compound according to at least one of claims 1 to 8 or a physiologically acceptable salt according to claim 9 is incorporated in one or more inert carriers and/or diluents by a non-chemical method.
18. Process for preparing a compound of general formula I according to claims 1 to 8,
35 characterised in that a compound of general formula II



wherein

R' denotes H, C_{1-4} -alkyl, $(C_{1-18}$ -alkyl)carbonyl, $(C_{1-18}$ -alkyl)oxycarbonyl, arylcarbonyl and aryl- $(C_{1-3}$ -alkyl)-carbonyl, wherein the alkyl or aryl groups may be mono- or polysubstituted by halogen;

R^{8a} , R^{8b} ,

R^{8c} , R^{8d} independently of one another have one of the meanings given for the groups R^6 , R^{7a} , R^{7b} , R^{7c} , denote a benzyl group or a $R^a R^b R^c Si$ group or a ketal or acetal group, while in each case two adjacent groups R^{8a} , R^{8b} , R^{8c} , R^{8d} may form a cyclic ketal or acetal group or a 1,2-di(C_{1-3} -alkoxy)-1,2-di(C_{1-3} -alkyl)-ethylene bridge, while the above-mentioned ethylene bridge forms, together with two oxygen atoms and the two associated carbon atoms of the pyranose ring, a substituted dioxane ring, and while alkyl, aryl and/or benzyl groups may be mono- or polysubstituted by halogen or C_{1-3} -alkoxy, and while benzyl groups may also be substituted by a di- $(C_{1-3}$ -alkyl)amino group; and

R^a , R^b , R^c independently of one another denote C_{1-4} -alkyl, aryl or aryl- C_{1-3} -alkyl, wherein the aryl or alkyl groups may be mono- or polysubstituted by halogen;

while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, preferably phenyl groups;

and R^1 to R^5 and R^6 , R^{7a} , R^{7b} , R^{7c} have the meanings given in claims 1 to 8,

is reacted with a reducing agent in the presence of a Lewis or Brønsted acid, while any protective groups present are cleaved simultaneously or subsequently;

if desired a compound of general formula I thus obtained wherein R^6 denotes a hydrogen atom, is converted by acylation into a corresponding acyl compound of general formula I, and/or

if necessary any protective group used in the reactions described above is cleaved and/or

if desired a compound of general formula I thus obtained is resolved into its stereoisomers
5 and/or


if desired a compound of general formula I thus obtained is converted into the salts thereof,
particularly for pharmaceutical use into the physiologically acceptable salts thereof.

10

19. Process according to claim 18, characterised in that the compound of general
formula II is obtained by the process described in claim 20 or 21.

15

20. Process for preparing compounds of general formula II



wherein

20

R' denotes H, C₁₋₄-alkyl, (C₁₋₁₈-alkyl)carbonyl, (C₁₋₁₈-alkyl)oxycarbonyl, arylcarbonyl and aryl-(C₁₋₃-alkyl)-carbonyl, wherein the alkyl or aryl groups may be mono- or polysubstituted by halogen;

25

R^{8a}, R^{8b},
R^{8c}, R^{8d} independently of one another have one of the meanings given for the groups R⁶, R^{7a}, R^{7b}, R^{7c}, denote a benzyl group or a R^aR^bR^cSi group or a ketal or acetal group, while in each case two adjacent groups R^{8a}, R^{8b}, R^{8c}, R^{8d} may form a cyclic ketal or acetal group or a 1,2-di(C₁₋₃-alkoxy)-1,2-di(C₁₋₃-alkyl)-ethylene bridge, while the above-mentioned ethylene bridge forms, together with two oxygen atoms and the two

30


associated carbon atoms of the pyranose ring, a substituted dioxane ring, and while alkyl, aryl and/or benzyl groups may be mono- or polysubstituted by halogen or C₁₋₃-alkoxy, and while benzyl groups may also be substituted by a di-(C₁₋₃-alkyl)amino group; and

R^a, R^b, R^c independently of one another denote C₁₋₄-alkyl, aryl or aryl-C₁₋₃-alkyl, wherein the aryl or alkyl groups may be mono- or polysubstituted by halogen;


while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, preferably phenyl groups;

and R¹ to R⁵ and R⁶, R^{7a}, R^{7b}, R^{7c} have the meanings given in claims 1 to 8,

wherein an organometallic compound (V) which may be obtained by halogen-metal exchange or by the insertion of a metal in the carbon-halogen bond of a halogen-benzylbenzene compound of general formula IV




wherein Hal denotes Cl, Br and I and R¹ to R⁵ are as hereinbefore defined, and optionally subsequent transmetallation, is added to a gluconolactone of general formula VI



wherein R^{8a}, R^{8b}, R^{8c}, R^{8d} are as hereinbefore defined, and

then the resulting adduct is reacted with water or an alcohol R'-OH, where R' denotes optionally substituted C₁₋₄-alkyl, in the presence of an acid and optionally the product obtained in the reaction with water wherein R' denotes H is converted in a subsequent reaction with an acylating agent into the product of formula II wherein R' denotes (C₁₋₁₈-alkyl)carbonyl, (C₁₋₁₈-alkyl)oxycarbonyl, arylcarbonyl or aryl-(C₁₋₃-alkyl)-carbonyl, which may be substituted as specified.

21. Process according to claim 20, characterised in that the organometallic compound (V) is a lithium or magnesium compound.
22. Process for preparing the compounds of general formula I according to claims 1 to 8, wherein R⁶, R^{7a}, R^{7b} and R^{7c} represent hydrogen, characterised in that a compound of general formula III



wherein

R^{8a}, R^{8b},

R^{8c}, R^{8d}

independently of one another have one of the meanings given for the groups R⁶, R^{7a}, R^{7b}, R^{7c}, but at least one of the groups R^{8a}, R^{8b}, R^{8c}, R^{8d} does not denote hydrogen, or denotes a benzyl group or a R^aR^bR^cSi group or a ketal or acetal group, while in each case two adjacent groups R^{8a}, R^{8b}, R^{8c}, R^{8d} may form a cyclic ketal or acetal group or a 1,2-di(C₁₋₃-alkoxy)-1,2-di(C₁₋₃-alkyl)-ethylene bridge, while the above-mentioned ethylene bridge forms a substituted dioxane ring together with two oxygen atoms and the associated two carbon atoms of the pyranose ring, and while alkyl, aryl and/or benzyl groups may be mono- or polysubstituted by halogen or C₁₋₃-alkoxy, and while benzyl groups may also be substituted by a di-(C₁₋₃-alkyl)amino group; and

R^a , R^b , R^c independently of one another represent C_{1-4} -alkyl, aryl or aryl- C_{1-3} -alkyl, while the alkyl or aryl groups may be mono- or polysubstituted by halogen;

5 while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, preferably phenyl groups;

and R^1 to R^5 , R^6 , R^{7a} , R^{7b} , R^{7c} have the meanings given in Claims 1 to 8,

10 is hydrolysed, and

if desired a compound of general formula I thus obtained wherein R^6 denotes a hydrogen atom is converted by acylation into a corresponding acyl compound of general formula I, and/or

15

if necessary any protective group used in the reactions described above is cleaved and/or

if desired a compound of general formula I thus obtained is resolved into its stereoisomers and/or

20


if desired a compound of general formula I thus obtained is converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof.

25

23. Process according to claim 22, characterised in that the compound of formula III is obtained by a process according to claim 18 or 19.


24. Compound of general formula IV

30




wherein Hal denotes chlorine, bromine or iodine and the groups R^1 , R^2 , R^3 , R^4 and R^5 are defined as in one or more of Claims 1 to 6.

25. Compound of formula IV according to claim 24, characterised by the formula



wherein Hal denotes chlorine, bromine or iodine and the groups R^1 , R^2 , R^4 and R^5 are defined as in one or more of Claims 1 to 6.

26. Compound of general formula II



wherein

R' denotes H, C_{1-4} -alkyl, $(C_{1-18}$ -alkyl)carbonyl, $(C_{1-18}$ -alkyl)oxycarbonyl, arylcarbonyl and aryl- $(C_{1-3}$ -alkyl)-carbonyl, wherein the alkyl or aryl groups may be mono- or polysubstituted by halogen;


R^{8a} , R^{8b} ,
 R^{8c} , R^{8d}

independently of one another have one of the meanings given for the groups R^6 , R^{7a} , R^{7b} , R^{7c} , or denote a benzyl group or a $R^aR^bR^cSi$ group or a ketal or acetal group, while in each case two adjacent groups R^{8a} , R^{8b} , R^{8c} , R^{8d} may form a cyclic ketal or acetal group or a 1,2-di(C_{1-3} -alkoxy)-1,2-di(C_{1-3} -alkyl)-ethylene bridge, while the above-mentioned ethylene bridge forms, together with two oxygen atoms and the two associated carbon atoms of the pyranose ring, a substituted dioxane ring, and while alkyl, aryl and/or benzyl groups may be mono- or polysubstituted by halogen or C_{1-3} -alkoxy, and while benzyl groups may also be substituted by a di- $(C_{1-3}$ -alkyl)amino group; and

R^a , R^b , R^c independently of one another denote C_{1-4} -alkyl, aryl or aryl- C_{1-3} -alkyl, while the alkyl or aryl groups may be mono- or polysubstituted by halogen;

5 while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, preferably phenyl groups;

and R^1 to R^5 are defined as in one or more of Claims 1 to 6.



INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/060098

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D309/10 C07D405/10 C07D409/10 C07D413/10 C07D417/10
A61K31/351 A61K31/381 A61K31/41 A61K31/4155 A61K31/422
A61K31/4245 A61K31/427 A61K31/443 A61K31/506 A61K31/501

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2005/092877 A (BOEHRINGER INGELHEIM INTERNATIONAL GMBH; BOEHRINGER INGELHEIM PHARMA G) 6 October 2005 (2005-10-06) claims 1,15	1-26
A	WO 2004/063209 A (BRISTOL-MYERS SQUIBB COMPANY; DESHPANDE, PRASHANT, P; ELLSWORTH, BRUCE) 29 July 2004 (2004-07-29) abstract	1-26
A	WO 02/083066 A (BRISTOL-MYERS SQUIBB COMPANY; GOUGOUTAS, JACK, Z) 24 October 2002 (2002-10-24) claims 1,7	1-26
	----- -/-- -----	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

20 June 2006

Date of mailing of the international search report

06/07/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bérillon, L

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/060098

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 01/27128 A (BRISTOL-MYERS SQUIBB COMPANY; ELLSWORTH, BRUCE; WASHBURN, WILLIAM, N;) 19 April 2001 (2001-04-19) claims 1,16</p> <p>-----</p>	1-26

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2006/060098

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005092877 A	06-10-2005	NONE	
WO 2004063209 A	29-07-2004	AU 2003299966 A1 BR PI0317929 A CA 2512389 A1 EP 1581543 A2 MX PA05007052 A	10-08-2004 11-04-2006 29-07-2004 05-10-2005 18-08-2005
WO 02083066 A	24-10-2002	AT 318272 T CA 2444481 A1 DK 1385856 T3 EP 1385856 A2 JP 2004536047 T	15-03-2006 24-10-2002 15-05-2006 04-02-2004 02-12-2004
WO 0127128 A	19-04-2001	AT 295848 T AU 781009 B2 AU 7848300 A BR 0014722 A CA 2388818 A1 CN 1407990 A CZ 20021285 A3 DE 60020259 D1 DE 60020259 T2 EP 1224195 A1 ES 2240179 T3 HK 1044541 A1 HU 0300393 A2 JP 2003511458 T MX PA02003625 A NO 20021721 A NZ 518029 A PL 355018 A1 PT 1224195 T TR 200200986 T2	15-06-2005 28-04-2005 23-04-2001 25-02-2003 19-04-2001 02-04-2003 12-02-2003 23-06-2005 19-01-2006 24-07-2002 16-10-2005 11-11-2005 28-06-2003 25-03-2003 23-10-2002 10-06-2002 27-08-2004 22-03-2004 29-07-2005 22-07-2002